INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY
WORLD HEALTH ORGANIZATION
SAFETY EVALUATION OF CERTAIN
FOOD ADDITIVES AND CONTAMINANTS
WHO FOOD ADDITIVES SERIES 40
Prepared by:
The forty-ninth meeting of the Joint FAO/WHO Expert
Committee on Food Additives (JECFA)
World Health Organization, Geneva 1998
AFLATOXINS
First draft prepared by
S. Henry1, F.X. Bosch2, J.C. Bowers1, C.J. Portier3,
B.J. Petersen4 and L. Barraj4
1 US Food and Drug Administration, Washington, DC
2 Institut d'Oncologia, Unitat d'Epidemiologia, Hospitalet del
Llobregat, Barcelona, Spain
3 National Institute of Environmental Health Sciences, Research
Triangle Park, NC, USA
4Novigen Sciences Inc., Washington, DC, USA (authors of section 4)
1. Explanation
2. Biological data
2.1 Biochemical aspects
2.1.1 Metabolism of aflatoxins
2.2 Toxicological studies
2.2.1 Acute toxicity
2.2.2 Special studies on reproductive toxicity
2.2.3 Special studies on genotoxicity
2.2.4 Special studies on immunosuppression
2.2.5 Factors modifying carcinogenicity of aflatoxins
2.2.6 Special studies on covalent binding of aflatoxin
residues with nucleic acids and proteins
2.2.7 Special studies on glucose tolerance
2.2.8 Special studies on effect of ammoniation of AFBI in
contaminated cottonseed
2.2.9 Special studies on aflatoxin and hepatitis B virus
infection in woodchucks, ducks, ground squirrels and
tree shrews
2.2.10 Observations in humans
2.2.10.1 Biomarkers of aflatoxin exposure
2.2.10.2 Mutations in p53 tumour-suppressor gene in
human hepatocellular carcinoma
2.2.10.3 Epidemiology of primary liver cancer
2.2.11 Summary of information on other aflatoxins
2.2.11.1 Aflatoxin B2
2.2.11.2 Aflatoxin G1
2.2.11.3 Aflatoxin G2
2.2.11.4 Aflatoxin M1
3. Estimating carcinogenic risks from the intake of aflatoxins
3.1 Information from various scientific disciplines and its
contribution to aflatoxin carcinogenic risk
3.1.1 Laboratory animal, mutagenicity and metabolic studies
3.1.2 Studies on the p53 gene
3.1.3 Epidemiological studies
3.1.4 Aflatoxin biomarker studies
3.2 General modelling issues
3.2.1 Choice of data
3.2.2 Measure of exposure
3.2.3 Measure of response
3.2.4 Choice of mathematical model
3.3 Potency estimates
3.3.1 Potency estimates based upon epidemiological data
3.3.2 Potency estimates not accounting for HBV infection
3.3.3 Potency estimates accounting for HBV infection
3.3.4 Potency estimates based on biomarker studies
3.3.5 Potency estimates from test species
4. Aflatoxin dietary intake estimates
4.1 Introduction
4.2 Background
4.3 Methods
4.3.1 Period of intake of relevance
4.3.2 Estimated levels of aflatoxins in foodstuff
4.3.3 Estimated intakes
4.4 Results
4.4.1 Aflatoxin levels in foods: general
4.4.2 Aflatoxin levels in foodstuffs: Occurrence data by
commodity
4.4.2.1 Amount of commodity imported
4.4.2.2 Accounting for the change in aflatoxin levels
during processing
4.4.3 National estimates of aflatoxin intake
4.4.3.1 Australia
4.4.3.2 China
4.4.3.3 European Union
4.4.3.4 USA
4.4.3.5 Zimbabwe
4.4.4 Relative impact of establishing maximum limits on
estimate of intake
4.4.4.1 Average aflatoxin concentrations using four
possible scenarios
4.4.4.2 Intake of total aflatoxins using four scenarios
4.4.4.3 Intake of aflatoxin b1 within four scenarios
4.4.5 Summary
5. Comments and evaluation
5.1 Aflatoxin potencies
5.2 Population risks
5.3. Conclusions
6. References
List of abbreviations
AAT alpha-1-antitrypsin
ADA aflatoxin-DNA adduct
AF aflatoxin (general)
AF-alb aflatoxin-albumin (adduct)
AFB1 aflatoxin B1
AFB2 aflatoxin B2
AFG1 aflatoxin G1
AFG2 aflatoxin G2
AFL aflatoxicol
AFM1 aflatoxin M1
AFP alpha-fetoprotein
AL ad libitum
ALT alanine aminotransferase
AM alveolar macrophage
APAT ambient temperature ammoniation procedure
BNF beta-naphthoflavone
CMI cell-mediated immunity
CR calorically restricted
CYP cytochrome P450
DHBV duck hepatitis B virus
DTH delayed type hypersensitivity
eAAIR estimated age adjusted incidence rate
EPHX epoxide hydrolase
GGT gamma-glutamyltranspeptidase
GHIS Gambia hepatitis intervention trial
GSHV ground squirrel hepatitis virus
GST glutathione S-transferase
GSTM1 glutathione S-transferase M1
HBV hepatitis B virus
HC high carbohydrate (diet)
HCC hepatocellular carcinoma
HCV hepatitis C virus
HF hypercaloric fat-containing (diet)
HPHT high temperature ammoniation procedure
IC isocaloric fat-containing (diet)
I3C indole-3-carbinol
LC liver cancer
LDH lactate dehydrogenase
MDA malonaldehyde
OECD Organisation for Economic Co-operation and Development
Orm matched odds ratio
PCR polymerase chain reaction
PHC primary hepatocellular carcinoma
PLC primary liver cancer
ROS reactive oxygen species
SeY selenium-enriched yeast extract
WHV woodchuck hepatitis virus
1. EXPLANATION
Aflatoxins B1, B2, G1, and G2 are mycotoxins that may be
produced by three moulds of the Aspergillus species: A. flavus,
A. parasiticus and A. nomius, which contaminate plants and plant
products. Aflatoxins M1 and M2, the hydroxylated metabolites of
aflatoxin B1 and B2, may be found in milk or milk products obtained
from livestock that has ingested contaminated feed. Of these
six aflatoxins, aflatoxin B1 is the most frequent one present in
contaminated samples and aflatoxins B2, G1 and G2 are generally not
reported in the absence of aflatoxin B1. Most of the toxicological
data relate to aflatoxin B1. Dietary intake of aflatoxins arises
mainly from contamination of maize and groundnuts and their products.
Aflatoxins were evaluated at the thirty-first meeting of the
Committee (Annex 1, reference 77), at which time the Committee
considered aflatoxin to be a potential human carcinogen. Sufficient
information was not available to establish a figure for a tolerable
level of intake. The Committee urged that the intake of dietary
aflatoxin be reduced to the lowest practicable levels so as to reduce,
as far as possible, the potential risk. A working group convened by
the International Agency for Research on Cancer also concluded that
naturally occurring aflatoxins are carcinogenic to humans1.
At the forty-sixth meeting (Annex 1, reference 122), potency
evaluations and population risk estimates were considered, and the
Committee recommended that these analyses be completed and presented
in an updated toxicological review.
At its present meeting, the Committee reviewed a wide range of
studies in both animals and humans that provided qualitative and
quantitative information on the hepatocarcinogenicity of the
aflatoxins. This monograph reviews the experimental evidence
concerning the carcinogenicity of the aflatoxins, evaluates the
potencies of these contaminants, links these potencies to intake
estimates, and discusses the impact of hypothetical standards on
sample populations and their overall risks.
The scientific literature on aflatoxins in the past thirty years
includes more than 3000 research articles. In 1971 aflatoxins were
reviewed in Volume 1 of the International Agency for Research on
Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risk and
again in Volume 56 of the IARC monographs in 1993. Aflatoxins were
last reviewed by the JECFA in 1987. A key recent publication in the
aflatoxin field was the review by Eaton & Groopman (1994). Eaton &
1 Some naturally occurring substances: food items and constituents,
heterocyclic aromatic amines and mycotoxins. Lyon, International
Agency for Research on Cancer, 1993 (IARC Monographs on the Evaluation
of Carcinogenic Risks to Humans, Vol. 56): 245-395.
Gallagher (1994) wrote a review of the mechanisms of aflatoxin
carcinogenesis. This review for JECFA will focus on key reports that
have appeared in the literature since the publication of the Eaton &
Groopman review and the 1993 IARC review.
2. BIOLOGICAL DATA
2.1 Biochemical aspects
2.1.1 Metabolism of aflatoxins
An excellent review on the cellular interactions and metabolism of
aflatoxin has been produced by McLean & Dutton (1995). Gorelick (1990)
compared metabolism of aflatoxin by different species. Guengerich
et al. (1996) discussed the involvement of cytochrome P450,
glutathione-S-transferase and epoxide hydrolase in the metabolism of
aflatoxin B1 (AFB1) and the relevance to risk of human liver cancer. A
wide variety of vertebrates, invertebrates, plants, bacteria and fungi
are sensitive to aflatoxins, but the range of sensitivity is wide for
reasons not yet fully understood (Cullen & Newberne, 1994). Two
important factors in species and strain variation of sensitivity are
1) the proportion of AFB1 that is metabolized to the 8,9-epoxide,
relative to other metabolites that are considerably less toxic, and 2)
the relative activity of phase II metabolism, which forms non-toxic
conjugates and inhibits cytotoxicity1. The 8,9-epoxide of AFB1 is
short-lived but highly reactive, and is believed to be the principal
mediator of cellular injury (McLean & Dutton, 1995).
Formation of DNA adducts of AFB1-epoxide is well characterized
(Cullen & Newberne, 1994). The primary site of adduct formation is the
N7 position of the guanine nucleotide.
It has been hypothesized that viral infection and associated
liver injury alter expression of carcinogen-metabolizing enzymes.
Kirby et al. (1994) tested this hypothesis in a hepatitis B virus
(HBV)-transgenic mouse model in which a synergistic interaction occurs
between AFB1 and HBV in the induction of hepatocellular carcinoma
(HCC). In this transgenic mouse lineage, overproduction of the HBV
large envelope protein results in progressive liver cell injury,
inflammation, and regenerative hyperplasia. Initially, two cytochrome
P450s important in AFB1 metabolism in the mice were identified -
CYP2a-5 and CYP3a, using specific antibodies and chemical inhibitors.
The expression of these P450 isoenzymes and an alpha-class glutathione
1 Phase I enzymes of major importance to carcinogen metabolism are
certain members of the superfamily (primarily within families 1-3) of
CYPs. In general, P450 enzymes catalyse the formation of more polar,
non-toxic products; however, bioactivation is sometimes a sequela. The
phase II enzymes of primary importance are the GST, which catalyse
conjugation of potentially toxic electrophiles to the tripeptide GSH,
generally rendering them non-toxic.
S-transferase (GST) isoenzyme, YaYa, was examined. Increased
expression and altered distribution of CYP2a-5 were demonstrated, by
immunohistochemical analysis, to be associated with the development of
liver injury in mice and to increase with age between 1 and 12 months.
CYP3a expression was also increased in HBV-transgenic mice, but the
increase was not as clearly related to age. GST YaYa levels were the
same in HBV-transgenic mice and their non-transgenic littermates of
all ages.
These results show that expression of specific cytochrome P450s
is altered in association with over-expression of HBV large envelope
protein and liver injury in this model. These findings may have
general relevance to human HCC, which is associated with a diverse
range of liver-damaging agents.
Judah et al. (1993) studied an aldehyde reductase in the rat,
which, in contrast with fractions from control animals, catalysed the
reduction of AFB1-dihydrodiol, in the dialdehyde form at physiological
pH values, to AFB1-dialcohol. This aldehyde reductase was expressed in
cytosolic fractions prepared from rat livers bearing pre-neoplastic
lesions, or following treatment with the anti-oxidant ethoxyquin. This
expression paralleled the development of resistance to the toxin. This
enzymatic mechanism might also have relevance in terms of the
development of resistance to other cytotoxic agents, the mechanism of
which involves metabolism to a reactive aldehyde. The authors
suggested that other systems, in particular human, be examined to
determine if this enzyme activity is expressed, and if so in what
circumstances, before its potential significance in the carcinogenic
process can be evaluated. For example, do the livers of humans
consuming diets contaminated with aflatoxins express such enzymes?
The monkey CYP1A1 has been expressed in BALB 3T3 A31-1-1 cells
and the expressed proteins were assayed for their capacity to activate
AFB1 and benzo[a]pyrene (B[a]P (Itoh et al., 1993). The transformed
cells were approximately 5.4- to 4.7-fold more sensitive to AFB1 and
B[a]P than the parental cells, respectively. The authors concluded
that monkey CYP1A1-cDNA encoded a functional protein and that the
expressed CYP1A1 enzyme is active in the activation of B[a]P as well
as AFB1 to produce toxic metabolites.
The combined presence of CYP1A2 and 3A4, both of which oxidize
AFB1 to the reactive AFB1-8,9-epoxide and to hydroxylated inactivation
products aflatoxin M1 (AFM1) and aflatoxin Q1 (AFQ1), substantially
complicates the kinetic analysis of AFB1 oxidation in human liver
microsomes. Gallagher et al. (1996) examined the reaction kinetics
of AFB1 oxidation in human liver microsomes (N = 3) and in human
CYP3A4 and CYP1A2 cDNA-expressed lymphoblastoid microsomes for the
purpose of identifying the CYP isoform(s) responsible for AFB1
oxidation at low substrate concentrations approaching those
potentially encountered in the diet. CYP3A4 with AFB1 was found to
have sigmoidal kinetics such that the rate of product formation fell
off quickly as the substrate concentration was reduced. CYP1A2 obeyed
Michaelis-Menten kinetics. Thus, at the low substrate concentrations
that probably occur in vivo, the formation of AFB oxide, as well as
AFB1 clearance, were predicted to be dominated by CYP1A2. Even at a
relatively higher substrate concentration, CYP1A2 formed approximately
three times as much AFB-exo-epoxide and generated three times as much
DNA binding as an equivalent amount of cDNA-expressed CYP3A4.
The authors pointed out that because AFB1 is highly lipophilic,
it is difficult to know how nominal concentrations of AFB in in
vitro microsomal preparations relate to concentrations in vivo.
The authors also discussed the work of Ueng et al. (1995), who
reported that CYP1A2 formed less AFB oxide than CYP3A4, using human
CYP1A2 and 3A4 proteins that were expressed in a bacterial expression
system. The discrepancy between the two studies, according to
Gallagher et al. (1996), may have been due to different sources of
P450s used in the two experiments.
Gallagher et al. (1996) concluded that the dominant route for
in vivo AFB1 activation at dietary concentrations obtained in human
liver is primarily thorough CYP1A2. Evidence that both CYP1A2 and 3A4
are involved in AFB1 metabolism in vivo is substantiated by
biomarker studies indicating the presence of AFM1 and AFQ1 in the
urine of individuals exposed to dietary AFB1 (Ross et al., 1992;
Qian et al., 1994). The ratio of activation:inactivation products
catalysed by CYP1A2 (roughly 2.5:1, AFBO:AFM1) and CYP3A4 (1:10;
AFBO:AFQ1) is likely to be a key determinant of the pathway and
biological consequences of in vivo AFB1 exposure. Unfortunately, the
actual urinary and faecal levels of these two metabolites, (in
particular, AFQ1 and possible secondary metabolites) following
exposure to AFB1 are not known. Thus, the relative ratio of these two
metabolites in individuals exposed to dietary AFB1, a key ratio, is
also unknown.
Sawada et al. (1993) show that human placental microsomes
activated AFB1, AFB1 showed relatively high mutagenic activity in the
Ames test when incubated with human placental microsomes. Addition of
alpha-naphthoflavone or aminoglutethimide, known inhibitors of
cytochrome P450 1A and P450 19, respectively, into the test system
partially inhibited the mutagen-producing activity.
Induction of glutathione-S-transferase placental form (GST-P)
positive hepatic foci has been examined by immunohistochemical
analysis in young male Fischer rats 3 weeks after a single i.p.
injection of AFB1 (Gopalan et al., 1993). Pretreatment of rats with
L-buthionine sulfoximine (BSO), a GSH depleter, at a dose of 4 mmol/kg
bw 4 and 2 hours before 1.0 mg AFB1 treatment enhanced both the number
of AFB1-induced hepatic foci and the area occupied by these foci by
approximately 400 and 575% above their respective controls without
affecting the mean diameter of these foci. Pretreatment of rats with
0.1% phenobarbital (PB) in their drinking water for 1 week before AFB1
(1 mg) treatment, inhibited AFB1-induced foci almost completely.
However, the number of AFB1-induced foci in PB-treated rats was not
significantly increased by BSO pretreatment.
Fetal rat liver has been shown to possess substantial levels of
glutathione-S-transferase (GST) activity toward AFB1-8,9-epoxide. The
enzyme responsible for this activity was an alpha-class GST
heterodimer comprising Yc1 and Yc2 subunits (Hayes et al., 1994).
The cDNAs encoding these polypeptides have been cloned and shown to
share approximately 91% identity over 920 base pairs, extending from
nucleotide -23 to the AATAAA polyadenylation signal. GST Yc2Yc2
expressed in Escherichia coli was found to exhibit 150-fold greater
activity toward AFB1-8,9-epoxide than GST Yc1Yc1. Comparison between
the structures of alpha-class GST suggested that tyrosine at residue
108 and/or aspartate at residue 208 is responsible for the high AFB1
detoxification capacity of Yc2. Immunoblotting and enzyme assays have
shown that liver from adult female rats contains about 10-fold greater
levels of Yc2 than is found in liver from adult male rats. This
sex-specific expression of Yc2 in adult rat liver may contribute to
the relative insensitivity of female rats to AFB1. Dietary
administration of oltipraz, a synthetic antioxidant which protects
against aflatoxin-hepatocarcinogenesis served as an inducer of GST
Yc2.
Gallagher & Eaton (1995) have investigated the biotransformation
of AFB1 in hepatic microsomal and cytosolic fractions from channel
catfish, an aquatic species shown to be refractory to AFB1 toxicity
and reported to be resistant to AFB1 hepatocarcinogenesis, and in
rainbow trout, a species sensitive to AFB1 toxicity and
hepatocarcinogenesis. AFB1 was poorly oxidized by channel catfish
microsomes, suggesting that the lack of microsomal AFB1 activation
together with the rapid conversion of AFB1 to aflatoxicol (AFL)
contributes to the apparent resistance of channel catfish to AFB1
toxicity and hepatocarcinogenesis.
Oltipraz is currently under evaluation as a possible
chemopreventive agent in humans. Primiano et al. (1995) investigated
the chemopreventive efficacy achieved by administration of
intermittent doses of oltipraz in rats. Fischer 344 rats were treated
with oltipraz (0.5 mmol/kg, p.o.) once weekly, twice weekly, or daily
over a 5-week period. After the first week, all rats were gavaged with
20 µg/kg AFB1 for 28 consecutive days. Livers were analysed 2 months
after the last AFB1 dose, and the volume of liver occupied by
glutathione-S-transferase (GST)-P positive foci, a presumptive marker
of neoplasia, was observed to be decreased by >95%, >97% or >99% in
livers of rats receiving once-, twice-weekly or daily oltipraz
treatments, respectively. The chemopreventive actions of oltipraz have
been associated with increases in the levels of phase 2 detoxifying
isozymes. Accordingly, GST conjugation activity measured with
1-chloro-2,4-dinitrobenzene as a substrate increased 1.5, 1.8 or
2.4-fold for the once-weekly, twice-weekly or daily treatments,
respectively, throughout a 7-day period. The authors suggested that
the protracted pharmacodynamic actions of oltipraz on enzyme induction
may account from the marked reduction in the hepatic burden of
AFB1-induced putative preneoplastic tumours after intermittent dosing.
Consequently, scheduling of intermittent dosing protocols may sustain
efficacy while improving drug tolerance and patient compliance over
long-term treatments. These properties of oltipraz increase its
attractiveness for clinical chemopreventive interventions, the authors
emphasized.
Langouet et al. (1995) investigated metabolism of AFB1 in
primary human hepatocytes with or without pretreatment by oltipraz.
AFM1, glutathione conjugates of AFB1 oxides and unchanged AFB1 were
quantified in cultures derived from eight human liver donors.
Parenchymal cell obtained from the three GST M1-positive livers
metabolized AFB1 to AFM1 and to AFB1 oxides derived from the isomeric
exo and endo-8,9-oxides, whereas no AFB1 oxides were formed in the GST
M1-null cells. Pretreatment of the cells with 3-methylcholanthrene or
rifampicin, inducers of CYP1A2 and CYP3A4 respectively, caused a
significant increase in AFB1 metabolism. Although oltipraz induced GST
A2, and to a lesser extent GST A1 and GST M1, it decreased formation
of AFM1 and AFB1 oxides, which involves CYP1A2 and CYP1A2. Inhibition
by oltipraz of AFB1 metabolism through a reduction in CYP1A2 and
CYP3A4 was also shown by decreased activity of their monooxygenase
activities toward ethooxyresorufin and nifedipine, respectively. The
significant inhibition by oltipraz of human recombinant yeast CYP1A2
and CYP3A4 was also shown. These results demonstrated that AFB1 oxides
can be formed by GST M1-positive human hepatocytes only, and suggested
that chemoprotection with oltipraz is due to an inhibition of
activation of AFB1 in addition to a GST-dependent inactivation of the
carcinogenic exo-epoxide.
AFB1-induced carcinogenesis has been shown to be both inhibited
and promoted by indole-3-carbinol (I3C), found in cruciferous
vegetables. Stresser et al. (1994a) examined the influence of
dietary treatment with I3C and the well-known Ah receptor agonist
beta-naphthoflavone (BNF) on the relative levels of different
cytochrome P-450 (CYP) isoforms known to metabolize AFB1 in male
Fischer 344 rats. After 7 days of feeding 0.3% I3C or 0.04% BNF alone
or in combination, the relative levels of hepatic CYP1A1, 1A2, 2B1/2
2C11 and 3A were assessed by laser densitometry of Western blots. Both
diets containing I3C markedly increased band densities of CYP1A1, 1A2,
and 3A1/2 with less effects on 2B1/2 and no effect on CYP2C11. BNF
also strongly increased band densities of CYP2C11, but had no effect
on CYP2C11 or 3A1/2, and repressed CYP2C11. In addition the in
vitro hepatic microsomal metabolism of AFB1 was examined at 16, 124,
and 512 TM substrate levels. The authors' results suggested that BNF
inhibits AFB1 carcinogenesis, in part by enhancing net production of
less toxic hydroxylated metabolites of AFB1, as a result of elevated
levels of P450, and that I3C may share this mechanism. However, other
mechanisms, such as direct inhibition of P450 bioactivation by I3C
oligomers, or induction of phase II enzymes, also appeared to
contribute.
Stresser et al. (1994a) also examined the influence of I3C and
BNF on the AFB1 glutathione detoxication pathway and AFB1-DNA
induction in rat liver. After 7 days of feeding approximately equally
inhibitory doses of I3C (0.2%) or BNF (0.04%) alone or in combination,
male Fischer 344 rats were administered [3H]AFB1 (0.5 mg/kg, 480
TCi/kg) i.p. and killed 2 hours later. All three diets inhibited
in vivo AFB1-DNA adduction. Using an improved HPLC method for
separation of the two isomeric forms of AFB1 8,9-epoxide-glutathione,
both I3C diets were shown to induce GST activities strongly toward
AFB1 exo-epoxide, whereas BNF alone induced activity weakly. Data
suggest that enhanced detoxication of AFB1 via increased glutathione
conjugation efficiency, as a result of elevated levels of the Yc2 GST
subunit, is one mechanism that contributes to a protective effect of
I3C against AFB1-induced preneoplastic lesions in the rat, and that
this mechanism also participates to a lesser degree in protection by
BNF.
The role of reactive oxygen species (ROS) in AFB1-induced cell
injury was investigated using cultured rat (male Fischer 344)
hepatocytes (Shen et al., 1995). Malonaldehyde (MDA) generation and
lactate dehydrogenase (LDH) release were determined as indices of
lipid peroxidation and cell injury, respectively. Exposure to AFB1 for
up to 72 hours resulted in significantly elevated levels of LDH being
released into the medium as well as the MDA generation in cultured
hepatocytes. These effects were dose-dependent, indicating that AFB1
was capable of inducing oxidative damages in the cell. Further, MDA
generation and LDH release were effectively inhibited by the addition
of the following: 1) superoxide dismutase (500 units/ml); 2) catalase
(1500 units/ml); 3) 10 mM desferrioxamine (a specific iron chelator),
or 4) 260 mM dimethyl sulfoxide (a hydroxyl radical scavenger). This
evidence therefore suggests that ROS, such as superoxide radicals,
hydroxyl radicals and hydrogen peroxides, are involved in AFB1-induced
cell injury in cultured rat hepatocytes, the authors concluded.
Kirby et al. (1993) examined liver tissues from 20 liver cancer
patients from Thailand, an area where the incidence of this tumour is
high and where exposure to aflatoxin occurs. The expression of hepatic
cytochrome P450s and GST was examined and this expression was compared
to the in vitro metabolism of AFB1. There was a >10-fold
inter-individual variation in expression of the various P450s
including CYP3A4 (57 fold), CYP2B6 (56-fold), and CYP2A6 (120 fold).
Microsomal metabolism of AFB1 to AFB1 8,9-epoxide and AFQ1, the major
metabolite produced, was statistically significantly correlated with
CYP3A3/4 expression and, to a lesser extent, with CYP2B6 expression.
There was a significantly reduced expression of major P450 proteins in
microsomes from liver tumours compared to microsomes from the paired
normal liver when analysed by Western immunoblot analysis.
The immunoreactive expression of the major human classes of
cytosolic GSTs (alpha, mu and pi) was also analysed in normal and
tumorous liver tissue. The expression of GSTA (alpha) and GSTM
(mu) class proteins was markedly decreased and GSTP (pi) increased
in the majority of tumour cytosols compared to normal liver. Cytosolic
GST activity was significantly lower in liver tumours compared to
normal liver. There was no detectable conjugation of AFB1 8,9-epoxide
to glutathione by cytosol either from tumorous or normal liver. Thus,
capacity of human cytosols to conjugate reactive AFB1 metabolites to
GSH resembled AFB1-sensitive species such as rat, trout and duck
rather than resistant species such as mouse and hamster. These data
indicate a strong capacity of multiple forms of human hepatic P450s to
metabolize AFB1 to both the reactive intermediate AFB1-8,9-epoxide and
the detoxification product AFQ1. The authors suggested, that, in view
of the lack of significant GST-mediated protection against AFB1 in
human liver, variations in expression of hepatic P450, due either to
genetic polymorphisms or to modulation by environmental factors, may
be important determinants in the risk of liver cancer development in
AFB1-exposed populations.
Liu et al. (1991) evaluated the functional significance of the
glutathione transferase (GST) mu polymorphism by measuring its
effect on AFB1-DNA adduct formation in vitro. Human liver cytosols
prepared from persons having low or high glutathione transferase
toward trans-stilbene oxide were incubated with human liver
microsomes, calf thymus DNA, and AFB1. AFB1-DNA binding was inhibited
to a greater extent in high conjugators than low conjugators; the
correlation between AFB1-DNA adduct concentrations and GST mu
activity was highly statistically significant. The authors suggested
that GST mu plays an important role in detoxifying DNA reactive
metabolites of AFB1, and this enzyme may be a susceptibility marker
for AFB1-related liver cancer.
Heinonen et al. (1996) studied the profile of AFB1 metabolism
and the extent of AFB1 binding to cell macromolecules in human liver
slices under experimental conditions that would allow direct
comparison to similar end-points in the rat, a species sensitive to
the carcinogenic actions of AFB1. Liver slices were prepared from
three individual human liver samples with a Krumdieck tissue slicer
and incubated with 0.5 µM [3H]AFB1 for 2 hours. Significant
inter-individual variations were observed in the rates of oxidative
metabolite formation and in specific binding to cell macromolecules.
The rates of oxidative metabolism of AFB1 to AFQ1, AFP1 and AFM1 in
the human liver samples were similar to those previously observed in
rat liver slices. AFB1-GSH conjugate formation was not detected in any
of the human liver samples, and yet specific binding of AFB1 to cell
macromolecules was considerably lower in the human liver slices
relative to that in rat liver slices. The authors postulated that
these studies suggest that an as yet unidentified protective pathway
may exit in human liver. These studies support the hypothesis that
humans do not form as much aflatoxin B1-8,9-epoxide as the rat, but
humans do not possess GST isozymes with high specific activity toward
the epoxide. Significant interindividual differences in AFB1
metabolism and binding between humans suggest the presence of genetic
and/or environmental factors that may make some humans more or less
susceptible to AFB1.
Gallagher et al. (1994) studied the metabolism of AFB1 in
microsomes derived from human lymphoblastoid cell lines expressing
transfected CYP1A2 or CYP3A4 (cytochrome P450) and in microsomes
prepared from human liver donors (n=4). The authors summarized their
findings as follows. Both CYP3A4 and CYP1A2 were involved in the
activation of AFB1 to the AFB1-8,9-epoxide; 1A2 appeared to have a
higher affinity for AFB1 and produced a higher ratio of activation
(AFB1-8,9-epoxide) to detoxification (AFM1) products, relative to 3A4.
3A4 may be expressed in human liver at a much higher level than 1A2,
such that in some individuals, 3A4 may be the predominant source of
AFB1-8,9-epoxide at low substrate concentrations, even though 3A4
produces AFQ1 predominantly. Such differences in the apparent kinetics
of these two P450s toward AFB1 indicate that the most important
determinant of individual susceptibility to AFB may well be the level
of expression of 1A2. Individuals with relatively high 1A2 expression
may be at particular risk for AFB1-induced DNA damage, since human
GSTs are relatively ineffective in detoxifying AFB1-8,9-epoxide.
Inhibition of 1A2 may prove to be an effective means of
chemointervention in AFB1-exposed populations. Of course, in vivo
human toxicity is ultimately determined by a complex set of processes.
In experiments by Ueng et al. (1995), human cytochromes P450
1A2 and 3A4 were expressed in Escherichia coli, purified, and used
in reconstituted oxidation systems. Relatively high catalytic
activities were obtained with such a system for AFB1
3 alpha-hydroxylation and 8,9-epoxidation. P450 3A4 was more active
than P450 1A2 in forming genotoxic AFB1 oxidation products; P450 3A4
formed AFQ1 and the exo-8,9-epoxide; P450 1A2 formed AFB1, some
AFQ1, and both the exo- and endo-8,9-epoxides. Plots of AFB1
3 alpha-hydroxylation and 8,9-epoxidation vs. AFB1 concentration
were sigmoidal in both human liver microsomes and the reconstituted
P450 3A4 system. The results were consistent, the authors
hypothesized, with the view that P450 3A4 is a major human liver P450
enzyme involved in AFB1 activation, although the in vivo situation
may be more complex due to the presence of the enzyme in the
gastrointestinal tract.
Guengerich et al. (1996) have reviewed a series of studies to show
the complexities encountered with metabolism of AFB1; the complexity
demonstrates the difficulties in doing molecular epidemiology studies,
even when a single chemical carcinogen has been identified. Figure 1
shows these metabolism complexities. With all the enzymes,
stereochemistry of the epoxide must be considered. In addition, the
P450s both activate and detoxify AFB1, and the effect of inducing
individual P450s is not easy to predict. P450 3A4 is expressed in the
small intestine, the site of absorption of orally ingested AFB1, where
the extent of detoxification is unknown. Even activation of AFB1 and
DNA alkylation in the small intestine may be considered to be a
detoxification process since the cells are sloughed rapidly, and
cancers of the small intestine are very rare.
2.2 Toxicological studies
2.2.1 Acute toxicity
No additional acute toxicity studies have been reported in the
literature since the review by Eaton & Groopman (1994).
2.2.2 Special studies on reproductive toxicity
Ankrah et al. (1993) exposed ddy mice to AFB1 and AFG1 via
their feed (4.8 ng AFG1, 0.8 ng AFB1 (or both) per kg bw per day while
in utero. Levels of aflatoxin used were realistic relative to the
level of human exposure currently seen in Ghanaian foods. Offspring of
these animals (control and aflatoxin-fed) were continued on the
respective diets received by the parent stock until sacrifice at six
months of age. Blood obtained by cardiac puncture was used to
determine haema-tological indices and the sera were used to determine
glucose, triglyceride, total protein and albumin. AFG1 caused
significant accumulation of only neutral fat in the liver, a slight
rise in serum triglyceride and intensified hepatorenal inflammation,
necrosis and bile duct proliferation. AFB1 caused the accumulation of
both neutral fat and fatty acids in the liver, and was cytotoxic to
the liver and kidney. Iron storage in the liver, haematological
indices, serum total protein and albumin levels were not affected by
the aflatoxins. At the level used, AFG1 was six times in excess of
AFB1, but the latter was more severe in the observed hepatorenal
effects.
The authors pointed out that the mouse liver has been shown to
metabolize aflatoxin in a manner similar in some ways to the human
liver, although not all investigators would agree on this point. Hence
they postulated that the action of aflatoxin on mouse organs may shed
light on aflatoxin cytotoxicity in humans; results of this study are
of particular relevance to population groups that ingest foods known
to contain mainly AFG1 and to some extent AFB1.
2.2.3 Special studies on genotoxicity
AFB1 covalently binds to DNA and efficiently induces G to T
trans-versions; codon 249, one site in p53, is a striking hot spot for
AFB1 mutagenesis (Sengstag & Wurgler, 1994). Often, such mutations are
followed by the loss of the second functional alleles of tumour
suppressor genes, a phenomenon called loss of heterozygosity. To test
whether mitotic recombination leading to loss of heterozygosity is
induced by certain carcinogens, the authors genetically engineered a
Saccharomyces cerevisiae tester strain so that it metabolized two
important classes of carcinogens including AFB1. Human cDNAs coding
for the cytochrome P450 (CYP) enzymes CYP1A1 or CYP1A2 in combination
with NADPH-CYP oxidoreductase in a strain heterozygous for two
mutations in the trp5 gene were inserted. AFB1, when activated
intracellularly in microsomes isolated from the yeast strains
containing either human CYP enzyme, significantly induced mitotic
recombination. The authors concluded that activated AFB1 is a potent
inducer of DNA recombination in S. cerevisiae strains harbouring
various heterologous xenobiotic-metabolizing systems.
Young weanling Swiss albino mice were orally administered crude
AFB1 in a dose mimicking human exposure, i.e., at 0.05 µg/kg bw per
day for 14 weeks (Sinha & Dharmshila, 1994). Vitamin A (retinol) was
orally administered along with the toxin at double (132 IU/kg bw per
day) the human equivalent therapeutic dose. The authors concluded that
vitamin A minimized the frequency of toxin-induced clastogeny in both
mitotic and meiotic chromosomes. The decreases in sperm count, as well
as increases in abnormality in the gross morphology of the sperm head,
as observed upon toxin treatment, was ameliorated by the vitamin A.
Marquez-Marquez et al. (1993) evaluated the effects of an AFB1
inactivating system with ammonia on the genotoxicity of AFB1 measuring
micronucleus (MN) and sister chromatid exchange (SCE) analyses. Four
groups of CD1 male mice were fed for 8 weeks with a special diet
mainly composed of maize: 1) uncontaminated; 2) uncontaminated/
inactivated; 3) contaminated/ inactivated; and 4) contaminated. The
inactivating treatment was performed with ammonium hydroxide by
homogeneously impregnating the grain and leaving it for 20 days in
hermetically closed plastic bags and then heating in an oven for 24
hours to eliminate the residual ammonia. AFB1 was quantified before
and after inactivation. MN was evaluated at weekly intervals in
peripheral blood; SCE was quantified in bone marrow cells at weeks 4
and 8. The results showed that mice fed with AFB1 contaminated/
inactivated maize had a 45% lower level of induced cytogenetic damage
than those animals fed with AFB1 contaminated (but not inactivated)
maize. A residual amount of AFB1 remaining after the inactivating
treatment and the reconversion back to AFB1 in the organism may
account for the remaining increased levels of SCE and MN.
Marquez-Marquez et al. (1995) evaluated the efficiency of the
AFB1 inactivating system with ammonia, as described above, and using
mice (male CD-1) and micronucleus (MN) and sister chromatid exchange
(SCE) analysis. Apparently this study was the same as that published
earlier.
Occupational exposures to respirable dusts contaminated with the
mycotoxin AFB1 have been associated with an increased incidence of
upper airway tumours. To investigate this possible etiology Ball
et al. (1995) compared the abilities of tracheal and lung S9 from
rabbit (male, New Zealand white), hamster (male Syrian Golden) and rat
(male Sprague-Dawley) to activate AFB1 to mutagens in Salmonella
typhimurium TA98. These species differ in airway morphology with
respect to numbers of metabolically active non-ciliated tracheal
epithelial cells. Tracheas from hamster and rabbit and lung from
rabbit were active in converting AFB1 to bacterial mutagens. Tracheas
from hamster were more efficient in activating AFB1 to mutagens than
lung, while rabbit lung was over 4 times more active in converting
AFB1 to mutagens than that from trachea. In all cases, AFB1 was more
mutagenic than B[a]P. The relative capabilities of trachea to activate
AFB1 were in agreement with the ability of cultured tracheas from
these species to form AFB1-DNA adducts. These results demonstrate that
AFB1 is activated more efficiently than B[a]P in the lung, and that
the metabolic capabilities of airway epithelium to activate AFB1 are
not predictable by airway morphology.
A study by Shi et al. (1995a) examined the effect of two
selenium compounds, namely, sodium selenite and selenium-enriched
yeast extract (SeY) on the cytotoxicity, DNA binding, and mutagenicity
of AFB1 in cultured Chinese hamster ovary (CHO) cells. CHO cells,
after treatment with 2 µg/ml selenite or 80 µg/ml SeY, exhibited
increased resistance to AFB1-induced cell killing. At a concentration
of 50 µg/ml AFB1, cell survival, measured by the clonogenicity assay,
was increased by 21- and 10-fold in selenite- and SeY-treated cells,
respectively. However, selenium treatment did not appear to affect
AFB1-DNA binding. Similarly, no effect was observed on AFB1
mutagenicity, as determined by the hypoxanthine-guanine phosphoribosyl
transferase (HPRT) gene mutation assay. The results showed that
selenium could effectively protect cells from AFB1 cytotoxicity in
cultured cells, but had no effect on AFB1-DNA adduct formation or
mutagenesis. The authors suggested that there are multiple pathways of
AFB1 toxicity and that selenium can modulate AFB1-induced cell killing
independent of its genotoxicity.
Rats and mice differ markedly in sensitivity to AFB1
hepatocarcinogenicity, the former being sensitive and the latter
resistant. The purpose of this study was to determine whether the
formation of AFB1-albumin (AF-alb) adducts was related to the
induction of cytogenetic changes in vivo as a step to understanding
whether such markers of exposure may be informative with respect to
genetic alterations important in the carcinogenic process (Anwar
et al., 1994). The comparison was made at two levels: between
species and between individuals within a species. Animals (male Helwan
Wistar albino rats and Swiss albino mice) were treated with single
doses of different concentrations of AFB1 between 0.01 and 1.0 µg
AFB1/g bw. The frequency of chromosomal aberrations and micronuclei in
the bone marrow was measured and compared to the level of AFB1 bound
covalently to albumin in the peripheral blood. Both chromosomal
aberrations and micronuclei were significantly increased in treated
rats compared to the control group at doses above 0.1 µg/g. In
contrast, in mice, a slight increase in chromosome aberrations was
seen in the highest dose group (1.0 µg/g), but no increase in
micronuclei was observed at any of the doses. The level of chromosomal
aberrations was about 10 times higher in rats than in mice at the
highest dose of AFB1. AFB1-albumin increased linearly with dose of
AFB1, and there were strong statistically significant correlations at
the individual rat level with both chromosomal aberrations.
The level of AF-alb adducts was higher for a given dose in rats
than mice, as has been seen for the level of liver DNA adducts in the
two species. The metabolic basis of these differences has been
investigated and has been shown to be associated with the expression
of a specific glutathione-S-transferase isoenzyme in mice, which
efficiently conjugates the AFB1-epoxide to glutathione.
In rats, the level of AF-alb adducts was strongly correlated with
the frequency of both micronuclei and chromosomal aberrations in the
bone marrow. An increase in adduct levels was seen with exposures as
low as a few ng AFB1/g bw, whereas the genetic alterations were only
increased above control levels at doses around 0.1 µg/g.
The authors suggested two considerations for interpretation of
the present studies. First, the cells in which the micronuclei and
chromosomal aberrations were examined are not the target cells for
AFB1 hepatocarcinogenesis, and second, that this type of genetic
marker is relatively non-specific. Thus, the genetic alterations being
measured are not directly relevant to the carcinogenic process; this
limitation may be overcome as sensitive molecular techniques are
developed to measure mutation induced by aflatoxin in specific gene
sequences in somatic cells (See Aguilar et al., 1993). Recent
studies by these authors (Wild et al., in preparation) suggest that
AF-alb adducts reflect the differing species sensitivity to AFB1
carcinogenesis. This peripheral blood marker could be an indicator of
risk of liver cancer development in addition to being a marker of
exposure, the authors suggest, as has been further supported by the
study of Ross et al. (1992), in which the level of AFB1-N7 guanine
adduct in the urine was related to the subsequent risk of developing
hepatocellular carcinoma in a Chinese cohort. This study will be
discussed in section 2.2.10.
2.2.4 Special studies on immunosuppression
The immunosuppressive potential of AFB1 was evaluated in growing
rats (Raisuddin et al., 1993). The weanling rats (species
unspecified) were sub-chronically exposed to 60, 300 or 600 µg AFB1/kg
bw for four weeks on alternate days by oral feeding. Various
parameters of cell-mediated immunity (CMI) and humoral immunity were
assessed in control and treated animals. CMI was evaluated by
measuring delayed type of hypersensitivity (DTH) response and humoral
immunity was measured by plaque forming (PFC) assay. The
lympho-proliferative response assay for T- and B-cells was also
performed. It was observed that AFB1 selectively suppressed
cell-mediated immunity in growing rats. AFB1 suppressed CMI at the 300
and 600 µg dose levels only as measured by DTH response assay. The
authors concluded that continuous low level exposure of aflatoxin to
the growing host may enhance its susceptibility to infection and
tumorigenesis.
Jakab et al. (1994) conducted experiments to demonstrate the
immunosuppressive effects of AFB1 ingestion, in this case respiratory
tract exposure to AFB1. Rats (male Fischer 344) and mice (female
Swiss) were exposed either by aerosol inhalation or intratrachael
instillation to AFB1. Nose-only inhalation exposure of rats to AFB1
aerosols suppressed alveolar macrophage (AM) phagocytosis at an
estimated dose of 16.8 µg/kg with the effect of persisting for
approximately 2 weeks. To determine whether another mode of
respiratory tract exposure, intratrachael instillation, reflected
inhalation exposure, animals were treated with increasing
concentrations of AFB1, which also suppressed AM phagocytosis in a
dose-related manner, albeit at doses at least an order of magnitude
more than that obtained by aerosol inhalation. Intratrachael
administration of AFB1 also suppressed the release of tumour necrosis
factor-alpha from AMs and impaired systemic innate and acquired immune
defences as shown, respectively, by suppression of peritoneal
macrophage phagocytosis and the primary splenic antibody response. The
authors concluded that experimental respiratory tract exposure to AFB1
suppressed pulmonary and systemic host defences; they indicated that
inhalation exposure to AFB1 is an occupational hazard where exposure
to AFB1-laden dust is common, such as in grain dust.
2.2.5 Factors modifying carcinogenicity of aflatoxins
Young adult male Fischer rats maintained on a reduced calory diet
(60% of ad libitum food consumption) for 6 weeks showed a decrease
in the binding of AFB1 to hepatic or renal nuclear DNA and a reduction
of AFB-induced hepatocellular damage (Chou et al., 1993). Repeated
dosing of rats with AFB1 resulted in the inhibition of hepatic and
renal DNA synthesis as measured by [3H]thymidine incorporation.
However, the rate of DNA synthesis was greater in ad libitum (AL)
rats than in calorically restricted (CR) animals. Three days after
AFB1 dosing, the rate of DNA synthesis had recovered to the control
level. Cell cycle analyses measured by a flow cytometric method on
kidney cells of both AL and CR rats showed that there were no
significant changes in cell populations in the S phase between these
two groups of rats. AFB1 inhibited the cell proliferation by 33% (on
average). The restoration of the cell proliferation in kidney cells
was found on the third day after AFB1 dosing. The rate of regenerative
cell proliferation was found to be slightly greater in AL rats than in
CR animals. The AFB1-induced regenerative DNA synthesis in both liver
and kidney was retarded by CR.
Youngman & Campbell (1992) demonstrated that with young Fischer
344 rats the post-initiation development of AFB1-induced
gamma-glutamyltranspeptidase-positive (GGT+) hepatic foci was
markedly inhibited by low protein feeding, even though the energy
intake was greater. These investigators also studied this dietary
effect upon the development of hepatic tumours and the correlation of
foci development with tumour development. Following AFB1 dosing (15
daily doses of 0.3 mg/kg each), animals were fed diets containing 6,
14 or 22% casein (5.2, 12.2 or 19.1% protein) for 6, 12, 40, 58 or 100
weeks. Foci at 12 weeks and tumours at 40, 58 and 100 weeks developed
dose-dependently to protein intake. Foci development, tumour
incidence, tumour size and the number of tumours per animal were
markedly reduced, while the time to tumour emergence was increased
with low-protein feeding. Non-hepatic tumour incidence also was lower
in the animals fed the lowest protein diet. Foci development indices
(foci number, per cent liver volume occupied) were highly correlated
with tumour incidence at 58 and 100 weeks (r = 0.90-1.00). Tumour and
foci inhibition occurred in spite of the greater energy intake.
Previous results from a large ecological study in 65 rural
counties in China suggested that primary liver cancer in humans
primarily is associated with chronic HBV infection, coupled with
nutritional factors (e.g., animal protein) that elevate plasma
cholesterol level and encourage cancer growth (Campbell et al.,
1990). To test this hypothesis, the authors investigated the effect of
dietary animal protein on tumour development in HBV transgenic mice.
Male F2 offspring of 50-4 HBV transgenic mice were randomly assigned
to 6, 14 and 22% dietary casein. Serum was collected from the retro-
orbital vein and was analysed for the level of hepatitis B virus
antigen (HBsAg), the products of the S-transgene. The increases from
baseline in S-gene product observed for the normal protein animal
(22%) at 3 months was inhibited in the mid- and low-protein animals by
42% and 72%, respectively, with a highly significant dose-response
relationship (P<0.001). Serum glutamic-pyruvic transaminase activity
was not affected by diet treatment. The authors concluded that their
results strongly suggest that dietary casein controls, in a
dose-response manner, S-transgene expression in these experimental
animals.
Hasler et al. (1994) fed Fischer 344 rats a low-fat high
carbohydrate (HC) diet, an isocaloric fat-containing (IC) diet, a
hypercaloric fat-containing (HF) diet or a commercial rodent chow. The
effects of these diets were studied on the binding of AFB1 to
exogenous DNA and on the activities of hepatic glutathione
transferases (GSTs), cytochromes 2B1 and 1A1. Microsome-mediated
binding of [3H]AFB1 to exogenous DNA was significantly lower in the
HC rats than in the chow- and IC-fed rats. No significant differences
were noted between HF and either HC or IC rats. There was no
significant difference in hepatic GST activity of rats fed the
different diets. The authors suggested that high carbohydrate/low fat
diets may reduce microsome-mediated epoxidation of AFB1 to a larger
extent than high-fat diets. In general, high-fat diets increased
cytochrome 1A1 and 2B1 activities relative to chow and
high-carbohydrate diet. This suggested greater detoxification of AFB1,
thus reducing the amount of AFB1 available for hepatic macromolecular
binding, the authors concluded.
An excellent review by Massey et al. (1995) covers the
biochemical and molecular aspects of mammalian susceptibility to AFB1
carcinogenicity. Important considerations include: 1) different
mechanisms for bioactivation of AFB1 to its ultimate carcinogenic
epoxide metabolite; 2) the balance between bioactivation to and
detoxification of the epoxide; 3) the interaction of AFB1 epoxide with
DNA and the mutational events leading to neoplastic transformation; 4)
the role of cyto-toxicity in AFB1 carcinogenesis; 5) the significance
of non-epoxide metabolites in toxicity; and 6) the contribution of
mycotoxin-unrelated disease processes.
2.2.6 Special studies on covalent binding of aflatoxin residues with
nucleic acids and proteins
Shi et al. (1994) studied the effect of selenium on AFB1-DNA
binding and adduct formation. Male Fischer 344 rats, fed with up to 8
mg/litre sodium selenite in drinking-water for 8 weeks, were given a
single i.p. dose of AFB1. The rats were killed 24 hours later and the
amount of AFB1 bound to hepatic DNA and the amount of DNA adducts
formed were determined. Selenium pretreatment resulted in a
dose-dependent inhibition of AFB1-DNA binding as well as adduct
formation. This was accompanied by an increase of reduced glutathione
(GSH) in the liver of selenium-treated animals. These results
suggested that selenium could effectively inhibit AFB1-induced DNA
damage, which may be partially responsible for its anticarcinogenic
effect against AFB1.
Choy (1993) has reviewed the dose-response induction of DNA
adducts by AFB1 and its implication to quantitative cancer risk
assessment. Dose-response curves of DNA adduct formation after
ingestion or injection treatments in the rat were reviewed; a linear
dose-response relationship was observed in both injection and
ingestion studies at low doses. The author concluded that this
observation is consistent with the assumption of the linear
dose-response risk assessment model for genotoxic agents and justifies
the use of this model for quantitative cancer risk assessment for
aflatoxins. The author also concluded that although AFB1-DNA adducts
generated in rats, mice and humans reflect the "molecular dose" and
DNA damage in the target organ, bypassing the need for interspecies
pharmacokinetic dose adjustments, it is not possible to extrapolate
from rodents to humans at this time because human DNA adduct data are
incomplete.
2.2.7 Special studies on glucose tolerance
Glyoxalase-1 activity plays an important role in glucose
metabolism and has been reported to be depressed in mice fed low
levels of AFB1 (Ankrah, 1995). In the present study, glyoxalase-1
activity, glucose tolerance and pancreatic beta cell sensitivity were
examined in mice (male and female ddy) fed 0.045 ng AFB1 plus 0.450 ng
ABG1/g feed prenatally and for 6 months after birth. After glucose
challenge, the ratios between 0- and 2-hour serum glucose levels were
significantly higher than controls, indicating an increase in
tolerance of glucose in the aflatoxin-fed mice with lower glyoxalase-1
activity. Pancreatic beta cell sensitivity to stimulation by
tolbutamide was similar in both groups. However, liver malonic
dialdehyde was significantly higher in the aflatoxin-fed mice,
suggesting that the altered tolerance for glucose in the aflatoxin-fed
mice might be a consequence of aflatoxin-mediated peroxidative action
in the liver, the authors suggested.
2.2.8 Special studies on effect of ammoniation of AFB1 in
contaminated cottonseed
The effectiveness of ammonia in inactivating aflatoxin in
contaminated cottonseed was investigated (Bailey et al., 1994). Two
aflatoxin-contaminated cottonseed lots were treated separately using
atmospheric pressure, ambient temperature ammoniation procedure (APAT)
or a high pressure, high temperature ammoniation procedure (HPHT), and
incorporated into dairy cow rations. Isocalorific diets containing 25%
defatted, dried milk from cows fed aflatoxin-contaminated cottonseed
without or with APAT or HPHT treatment, or an aflatoxin-free human
grade commercial milk powder, were then fed for 12 months to rainbow
trout (Oncorhynchus mykiss). AFM1 concentrations in milk powders
without and with seed treatment were: APAT, 85 and <0.05 µg/kg; HPHT,
32 and <0.05 µg/kg. In the APAT experiment, trout consuming the diet
containing milk from cows fed the aflatoxin-contaminated cottonseed
had a 42% incidence of hepatic tumours; APAT cottonseed treatment
reduced this to 2.5%. Positive controls were included to demonstrate
trout responsiveness. AFB1 fed continuously for 12 months at 4 µg/kg
resulted in a 34% tumour incidence, whereas positive controls fed 20
µg AFB1/kg, 80 µg AFM1/kg, or 800 µg AFM1/kg for 2 weeks and killed 9
months later had a 37, 5.7 and 50% incidence of tumours, respectively.
The authors concluded that APAT ammonia treatment of
aflatoxin-contaminated dairy cattle cottonseed feedstock abolished the
detectable transfer of AFM1 or AFB1 into milk powder, and greatly
reduced the carcinogenic risk posed by any carry-over of aflatoxins or
their derivatives into milk.
In addition, the results confirm AFM1 to be a lower level
hepatocarcinogen in comparison with AFB1 in the trout carcinogenicity
assay. In the separate HPHT experiment, no tumours were observed in
the livers of trout fed diets containing milk from either the
ammonia-treated or untreated source, or the control diet containing 8
µg AFM1/kg. Positive controls fed 64 µg AFB1/kg for 2 weeks exhibited
a 29% tumour incidence 12 months later. Thus in this experiment,
neither AFM1 at 8 µg/kg nor any HPHT-derived aflatoxin derivatives
that might have been carried over into milk represented a detectably
carcinogenic hazard to trout, the authors conclude.
2.2.9 Special studies on aflatoxin and hepatitis B virus infection in
woodchucks, ducks, ground squirrels and tree shrews
Interactive hepadnavirus and chemical hepatocarcinogenesis has
been studied in woodchucks inoculated as newborns with woodchuck
hepatitis virus (WHV), which is closely related to the human hepatitis
B virus (Bannasch et al., 1995). When the woodchucks reached 12
months of age, AFB1 was administered in the diet at dose levels of 40
µg/kg bw per day for 4 months and subsequently 20 µg/kg bw per day
(5 days/week) for a lifetime. WHV DNA was demonstrated by Southern
blot hybridization in the serum and by PCR in the serum and/or liver
tissue. The histomorphology and cytomorphology of the liver were
investigated by light and electron microscopy. WHV carriers with and
without AFB1 treatment developed a high incidence of preneoplastic
foci or altered hepatocytes, hepatocellular adenoma and hepatocellular
carcinomas that appeared 6-26 months after the beginning of the
combination experiment. Administration of AFB1 to WHV carriers
resulted in a significantly earlier appearance of hepatocellular
neoplasms and a higher incidence of hepatocellular carcinomas compared
to WHV carriers not treated with AFB1. Neither hepatocellular adenomas
nor carcinomas (but preneoplastic foci of altered hepatocytes) were
detected in woodchucks receiving AFB1 alone, and no preneoplastic or
neoplastic lesions were found in untreated controls.
The authors pointed out that these results provide conclusive
evidence of a synergistic hepatocarcinogenic effect of hepadnaviral
infection and dietary AFB1. The striking similarities in altered
cellular phenotypes of preneoplastic hepatic foci similarities in
altered cellular phenotypes of preneoplastic hepatic foci emerging
after both hepadnaviral infection and exposure to AFB1 suggested
closely related underlying molecular mechanisms that may be mainly
responsible for the synergistic hepatocarcinogenic effect of these
oncogenic agents.
In addition, the authors observed that the decisive role of the
chronic WHV infection for hepatocarcinogenesis became particularly
evident in those animals that seroconverted after 1 year and showed
neither a chronic active hepatitis nor hepatocellular neoplasms, no
matter when AFB1 was given. From this observation, the authors
concluded that chronic hepatitis is not an absolutely necessary
condition for the development of HCC in WHV carriers.
To determine whether p53 mutations are common to HCCs of hosts
infected with related hepadnaviruses with and without treatment with
aflatoxin, Rivkina et al. (1994) studied the occurrence of mutations
in the p53 gene in HCCs of ground squirrels and woodchucks with a
history of infection with ground squirrel hepatitis virus (GSHV) and
woodchuck hepatitis virus (WHV). Sequencing of wild type p53 genes
from ground squirrels and woodchucks revealed remarkable homology
between the two species; using direct polymerase chain reaction
sequencing, the investigators analysed the state of the p53 gene in 20
HCCs from ground squirrels (2 uninfected, 7 with past and 11 with
ongoing infection with GSHV) and in 11 HCCs from woodchucks
persistently infected with WHV. Five GSHV carrier and two uninfected
ground squirrels received i.p. administration of AFB1. Only one
mutation - located in codon 176 of exon 5 - in the p53 gene of the
tested animals was detected and that in a GSHV-positive ground
squirrel treated with AFB1. The investigators suggested that in view
of the considerably lower apparent rate of mutations in comparison to
human HCCs, other etiological factors may be of greater significance
in the development of HCC in ground squirrels and woodchucks.
The unique mutation from G to T at the third base in codon 249
observed in human hepatocellular carcinoma has been suggested to be
linked to aflatoxin exposure. Imazeki et al. (1995) studied six
ducks with HCC, three of which were infected with duck hepatitis B
virus and five of which were fed a diet containing AFB1 for 1-2 years.
Liver tissues were analysed for the presence of point mutations at
this codon of the p53 gene by polymerase chain reaction and direct
nucleotide sequencing. None of the six ducks with HCC showed the
change at this codon regardless of duck hepatitis B virus infection.
Integration of duck hepatitis B virus DNA into the host genome was not
observed in two ducks that were chronically infected with the virus
and treated with AFB1. A third duck from Qitong Province in China,
where HBV and AFB1 are risk factors for HCC in humans, did show viral
integration. This suggested, in the opinion of the authors, that AFB1
itself might not be involved in the unique mutation at codon 249 in
hepatocarcinogenesis, or that other factors coincident with aflatoxin
may be responsible for this unique mutation.
Cova et al. (1996) used a Pekin duck model to examine the
effect of congenital duck hepatitis B virus (DHBV) infection and AFB1
exposure in the induction and development of liver cancer. The study
of the two major risk factors in the development of HCC, i.e.,
persistent hepatitis virus infection and exposure to dietary
aflatoxins, has been hampered by lack of an animal model, and these
experiments were undertaken to this end. AFB1 was administered to
groups of 13 DHBV infected or non-infected ducks at two doses (0.08
and 0.02 mg/kg) by i.p. injection once a week from the third month
posthatch until they were sacrificed 2.3 years later. Two control
groups of ducks not treated with AFB1 (one of which was infected with
DHBV) were observed for the same period. Higher mortality was observed
in ducks infected with DHBV and treated with AFB1 compared to
non-infected ducks treated with AFB1 and other control ducks. In the
groups of non-infected ducks treated with high and low doses of AFB1,
liver tumours developed in 3 out of 10 and 2 of 10 ducks,
respectively. In infected ducks treated with the high dose, 3 of 6
showed liver tumours; there were none with the low dose of AFB1. No
liver tumours were observed in the two control groups. Ducks infected
with DHBV and treated with AFB1 showed more pronounced periportal
inflammatory change, fibrosis and focal necrosis compared to other
groups. All DHBV carrier ducks showed persistent viraemia throughout
the observation period. An increase of viral DNA titres in livers and
sera of AFB1-treated animals compared to infected controls was
frequently observed.
No DHBV DNA integration into the host genome was observed,
although in one hepatocellular carcinoma from an AFB1-treated duck, an
accumulation of viral multimer DNA forms was detected. Unlike the
situation observed for woodchuck and ground squirrel, HCC has rarely
been associated with DHBV infection or integration of viral DNA in the
duck. HCC has to date been reported only in Chinese ducks from
Chi-tung County, not always associated with detectable virus, and with
only a single reported case of integrated DHBV. Colonies of
DHBV-infected ducks from other parts of the world do not develop HCC.
Prevalence of liver tumours observed in Chi-tung County ducks
reportedly correlated with the AFB1 food contamination and with the
incidence of primary liver cancer in these areas.
The authors observed a lower level of AFB1 binding to liver DNA
and plasma protein in the DHBV-infected ducks compared to non-infected
ducks after a single dose of AFB1; this finding appeared inconsistent
with the hypothesis that DHBV infection could increase the metabolic
activation of AFB1, as has been observed in woodchucks and in some
human data. The investigators noted that their observations were made
at a single dose at a single exposure and using one specific age of
ducks; all of these factors could have influenced the AFB1-DNA adduct
level.
Yan et al. (1996) reported the successful establishment of an
animal model in tree shrews (Tupaia belangeri chinensis) captured
from the wild and experimentally infected with human hepatitis B
virus. In animals exposed to AFB1 and infected with HBV, the incidence
of HCC was significantly higher than in the animals solely infected
with HBV or exposed to AFB1. AFB1-exposed animals received a total
dosage of 15-16 mg/animal. No HCC or precancerous lesions were found
in the controls that were neither HBV-infected nor AFB1-exposed. HBV
DNA and the protein it encodes were detected in the cancer cells
and/or the surrounding hepatocytes. Integration of HBV DNA into the
host liver genome was found during hepatocarcinogenesis among the
animals infected by HBV.
The investigators pointed out that the cumulative dose of AFB
used in their experiment was much lower than those (24-66 mg/animal)
used in previous experiments on tree shrews where HCC was seen. This
suggested that HBV infection might increase the hepatocarcinogenic
effect of AFB1. The occurrence of precancerous GT foci in the tree
shrews exposed only to AFB1 was much more frequent than in those
infected by HBV alone. Among the animals exposed to the same dose of
AFB1, the gamma-glutamyltranspeptidase (GGT) foci were more numerous
and larger in HBV-infected than in uninfected animals during the late
state (after the 83rd week), but not at the early state. This suggests
that, although both AFB1 and HBV may induce GGT foci and have a
synergistic effect, the effect of HBV is weaker and slower than that
of AFB1.
2.2.10 Observations in humans
2.2.10.1 Biomarkers of aflatoxin exposure
A key issue in the use of aflatoxin biomarkers is whether the
ratio of AFB1-albumin adduct to DNA adduct suggested in rodent
experiments is the same in humans (Wild et al., 1996). Direct
evidence for this is not available due to the limitation of measuring
DNA adducts in human liver. The human populations where AFB1 intake
vs. AFB1-albumin adduct relationship has been examined are populations
in which aflatoxin intake is relatively high. Examination of the
relationship in low-exposure populations would be important to test
whether the linear dose-response relationships seen in rats at
exposures as low as 1 ng AFB1/kg bw are also observed in man. There
are some data discussed in Wild et al. (1996) indicating that the
amounts of AFB1 intake bound to albumin are similar for rats and
humans; assuming that the majority of AFB1-DNA adducts are formed in
liver, then the initial ratio between the serum albumin and liver DNA
adducts would be expected also to be similar in humans and Fischer
rats. However, the capacity of human intestine to metabolize AFB1 must
be further explored to clarify this point.
It would appear that the AFB1-albumin adduct in peripheral blood
is a reliable marker of AFB1-DNA adducts in the liver in rodents (Wild
et al., 1996). Both of these parameters are at least qualitatively
associated with species susceptibility to AFB1 hepatocarcinogenesis.
Cross-species extrapolation to man suggests that the amount of
AFB1-albumin formed for a given exposure more closely approximates
that in the sensitive species rather than the resistant, and indicates
that the Fischer rat may be a more appropriate model than the mouse
for molecular dosimetry studies of AFB1 when, for example, validating
approaches for chemoprevention studies.
However, carcinogenesis is a multistep process; as pointed out in
Wild et al. (1996) AFB1-albumin adduct is acting as a surrogate
marker only for one critical step, the formation of AFB1-DNA adducts
in the target cell. The relationship between this marker and the
genetic consequences of exposure as well as the quantitative
association with HCC risk in man remain to be determined. In addition,
HBV and possibly HCC infection, are major risk factors. The
availability of more reliable markers of biologically effective dose
of AFB1 should contribute to improving attempts to understand the
mechanism of interaction between these two and other risk factors.
2.2.10.2 Mutations in p53 tumour-suppressor gene in human
hepatocellular carcinoma
Molecular epidemiological studies have found that a G to T
mis-sense mutation at the third base of codon 249 of the p53 gene,
effecting an arginine to serine substitution, occurs in high frequency
(up to 67%) in human liver tumours in regions with high risk of
aflatoxin exposure, but not in regions of low aflatoxin exposure
(Ozturk, 1991). Hsieh & Atkinson (1995) performed experiments to
confirm this, using liver tissue from liver cancer patients in Taiwan
and Japan. This was analysed for the presence of aflatoxin-DNA adducts
(ADA) as a marker for aflatoxin exposure and an AGG to AGT
transversion at codon 249 of the p53 gene. Ten per cent of samples
containing ADA, indicating definite exposure of the subjects to
aflatoxin, were found to harbour the codon 249 mutation, whereas 18%
of the samples with no detectable adducts also contained the mutation.
Since the presence of ADA in the liver tissue samples is an indication
of definite recent exposure of the liver cancer patients to aflatoxin,
these data indicated that the codon 249 mutation is not a high
frequency event associated with recent aflatoxin exposure. If recent
exposure to aflatoxin is indeed involved in the late stage
hepatocarcinogenesis, these data suggested that it is through some
mechanism other than codon 249 mutation. If either mutation at codon
249 of the p53 gene or exposure to aflatoxin is involved in earlier
stages of hepatocarcinogenesis, whether codon 249 of the p53 gene is a
"hot spot" for aflatoxin attack could be shown by the present
experiment, the authors concluded.
The tumour suppressor p53 exerts important protective functions
towards DNA-damaging agents (Gerbes & Caselmann, 1993). Its
inactivation by allelic deletions or point mutations within the p53
gene as well as complex formation of wildtype p53 with cellular or
viral proteins is a common and crucial event in carcinogenesis.
Mutations increase the half-life of the p53 protein allowing the
immunohistochemical detection and anti-p53 antibody formation.
Distinct G to T mutations in codon 249 leading to a substitution
of the basic amino acid arginine by the neutral amino acid serine are
responsible for the altered functionality of the mutation gene product
and were originally identified in 8 of 16 Chinese and 5 of 10 African
HCC patients, both groups living in regions with traditionally high
exposure to mycotoxins. None of these mutations was detectable in 20
patients with HCCs recently studied in the United Kingdom; only two of
13 HCC DNAs from Germany displayed a C to T and a T to A transversion,
respectively, in codons 257 or 273, but not in codon 249. An average
p53 gene nutation rate of 25% is currently assumed for high-AFB1
exposure regions; this is double the rate observed in low-AFB1
exposure countries. The authors concluded that although many HCC
patients displaying P53 mutations also suffer from HBV infection,
which itself can lead to rearrangement of P53 coding regions or induce
the synthesis of viral proteins possibly interacting with p53, the
specific G to T transversion within codon 249 of the P53 gene seems to
directly reflect the extent of AFB1 exposure and is not pathognomonic
for all HCCs.
Yap et al. (1993) analysed 24 HCC liver biopsy samples from
patients in Durban, South Africa, for p53 mutations and HBV infection.
One patient was negative for HBV (Hbsag, anti-HBcAb, anti-HBsAb) and
possessed the p53 249 mutation (which results in an arginine to serine
substitution). The authors suggested that HBV infection or integration
increases the likelihood of, but is not essential for, this p53
"hot-spot" mutation in HCC. AFB1 or other as yet unidentified
environmental carcinogens and cofactors are implicated; the mechanisms
by which cells exposed to these agents acquire such a specific
mutation and then expand clonally remains to be elucidated.
The subject of the mutation at codon 249 of the p53 tumour
suppressor gene has continued to be the subject of much research.
Fifty-eight per cent of HCCs from Quidong, China, contain this
mutation which is rarely seen in HCCs from Western countries (Aguilar
et al., 1994). The population of Qidong is exposed to high levels of
AFB1 and this toxin has been shown to induce the same mutation in
cultured human HCC cells. To investigate the role of AFB1 and of these
p53 mutations in hepatocarcinogenesis, normal liver samples from the
USA (5), Thailand (3), and Qidong (14) (where AFB1 exposures are
negligible, low, and high, respectively), were examined for p53
mutations. The frequency of the AGG to AGT mutation at codon 249
paralleled the level of AFB1 exposure, which supports the hypothesis
that this toxin has a causative - and probably early - role in
hepatocarcinogenesis. However, a role for other carcinogens cannot be
ruled out, the authors point out; bulky heterocyclic amines in cooked
foods and oxidants released by inflammatory leukocytes possess the
same specificity for G to T transversion and HBV infection is
associated with inflammation. All of the liver samples from Qidong and
Thailand were from HBV-infected individuals.
The presence of elevated frequencies of codon 249 AGT mutations
in the non-malignant tissue of HCC patents from Qidong suggested that
the mutagenic event occurred early in hepatocarcinogenesis. In
contrast, p53 mutations in HCCs from geographic areas with low
exposure to AFB1 could be late events. For example, p53 mutations have
been observed more frequently in large tumours and in advanced grades
of malignancy in HCCs from Japan. In other organs, such as the colon
and the bladder, p53 mutations are thought to occur late in
tumorigenesis. However, the methods used in previous work may not have
been sensitive enough to detect mutations at early stages of
tumorigenesis.
Fujimoto et al. (1994) tested the hypothesis that exposure to
AFB1 alone or coincident with other environmental carcinogens might be
associated with allelic losses occurring during development of human
hepatocarcinogenesis (HCC) in China. The HCCs were obtained from two
different areas in China: Qidong, where exposure to HBV and AFB1 is
high; and Beijing, where exposure to HBV is high, but that to AFB1 is
low. Tumours were analysed for mutations in the p53 gene and loss of
heterozygosity for the p53, Rb and APC genes and at marker loci on
chromosomes 4, 13 and 16. The data indicated that mutation and/or loss
of heterozygosity in the p53 gene, independent of the 249 mutation,
played a critical role in the development of HBV-associated HCCs in
China. The authors postulated that different mechanisms appeared to be
responsible for the development of HCC in Beijing and may have
resulted from exposure to unknown environmental carcinogens or a
different subtype of HBV. Also, the results demonstrated that multiple
alterations in DNA located on different chromosomes may be involved in
the development of HCC.
Additional support for the etiological role of AFB1 in
hepatocarcinogenesis in regions of the world with AFB1-contaminated
food has come from the studies of Aguilar et al. (1993). These
investigators studied the mutagenesis of codons 247-250 of p53 by rat
liver microsome-activated AFB1 in human HCC cells HepG2 by restriction
fragment length polymorphism/polymerase chain reaction genotypic
analysis. AFB1 preferentially induced the transversion of G to T in
the third position of codon 249, and also induced G to T and C to A
transversions into adjacent codons, albeit at lower frequencies. Since
the latter mutations are not observed in HCC, the investigators
concluded that both mutability on the DNA level and altered function
of the mutant serine 249 p53 protein are responsible for the observed
mutational hot spot in p53 HCC from AFB1-contaminated areas. The fact
that this mutation is only rarely found in HCC from low AFB1 regions
indicates that it is not a prerequisite for hepatocarcinogenesis;
perhaps HBV and the mutant serine 240 p53 protein play a synergistic
role.
In a later study, Aguilar et al. (1995) examined normal liver
samples from the USA, Thailand and Qidong, where AFB1 exposures are
negligible, low and high, respectively, for p53 mutations. The
frequency of the AGG to AGT mutation at codon 249 paralleled the level
of AFB1 exposure, which, according to the authors, provides additional
support for the hypothesis that this toxin has a causative and
probably early role in hepatocarcinogenesis.
Hulla et al. (1993) analysed the p53 gene at the site
corresponding to codon 249 of the human gene in AFB-induced
preneoplastic hepatic nodules from rats. No mutations were detected in
the tissues examined. Thus, at least in the rat, the authors suggested
that AFB exposure alone may not be sufficient for the specificity of
p53 mutations observed in HCC. The selective mutations have been
identified only in populations at risk for hepatitis B; it is possible
that both AFB1 and chronic hepatitis are essential for mutation at
codon 249 in the human p53 gene.
In another study in rats, Liu et al. (1996) looked at the
effects of AFB1 on the p53 locus at the preneoplastic stage of rat
liver oncogenesis. Male Wistar rats received a single dose of 1.5 mg
AFB1/kg bw by a gastric tube. Liver biopsies over a period of one year
were examined for aberrations of the p53 gene together with the
expression of placental GST, a marker for preneoplasia.
Immunohistochemistry, Western blot, polymerase chain
reaction-single-strand conformation polymorphism and DNA sequencing
techniques were used. AFB1 induction resulted in GST overexpression,
forming GST-positive multi-foci and nodules of hepatocytes but no
aberrations in the p53 expression and the microstructure of exons 5-8
of the p53 gene. Thus, the authors concluded that p53 mutations might
not occur at this early stage of AFB1-induced hepatocarcinogenesis.
Shi et al. (1995b) characterized p53 mutations in 44
hepatocellular carcinomas from Chinese patients residing in a
high-incidence area. In contrast to HCCs from other high HCC incidence
areas with endemic aflatoxin exposures, in which codon 249 is a
mutational hotspot, no mutations were observed at codon 249. The
authors concluded that risk factors other that dietary exposure to
aflatoxin may contribute to the high HCC incidence in Singapore.
Liang (1995) recently reviewed the relationship of p53 proteins
and AFB1. He pointed out firstly that the murine mutant p53 gene
p53Ser249 appears to have a hepatocyte-specific phenotype, which
suggests that this gene may interact with cellular factors(s) in a
liver-specific manner to alter the growth property of hepatocytes. It
is not known if the human form of p53Ser249 exhibits the same
properties. Secondly, cooperative interaction of this p53 mutation and
viral-induced cellular changes are probably involved in the
transformation of hepatocytes in situations where aflatoxin exposure
and hepatitis viral infection are evident. Recent studies of
non-aflatoxin-associated HCC showed that p53 mutations are not as
common as other human malignancies. This difference could be explained
by the relatively low proliferation rate of hepatocytes as compared
with other epithelial cells, such as colonic mucosa and mammary gland.
Because p53 plays a critical role in "damage control" of proliferating
cells and in regulation of abnormal proliferation, it is reasonable to
speculate that p53 mutations may play a lesser role in
hepatocarcinogenesis. However, dysregulated p53 function may still be
an important step in this process, in view of the recent observation
that HBX protein encoded by HBV appears to interact with p53 and
inhibit its function.
Thirdly, it has not been possible to induce the same p53 mutation
with aflatoxin exposure in a murine model, which casts a shadow of
doubt on the applicability of studies in the murine model to human
hepatocarcinogenesis. Liang (1995) recommended using human p53 genes
to perform parallel experiments.
Harris (1995) has also reviewed this subject. He reiterated that
in high-incidence liver cancer areas such as China and Mozambique, the
high frequency of G:C to T:A transversions in human hepatocellular
carcinomas in this region could be due to the high mutability of the
third base of codon 249 by AFB1 or a selective growth advantage of
hepatocyte clones carrying this specific p53 mutant in liver
chronically infected with HBV. The third base of codon 240 in a human
liver cell line exposed to AFB1 has been shown to be preferentially
mutated, and transfected 240Serp53 mutant enhances the growth rate of
the p53 null hepatocellular carcinoma cell line Hep3B.
The hypothesis that some of the mutations observed in the p53
tumour-suppressor gene may be specific markers of exposure to
aflatoxin may represent a real breakthrough in the field of liver
cancer epidemiology. In particular, the confirmation of the
specificity of the p53/aflatoxin association could be useful in
assessing and quantifying the responsibility of aflatoxin as an
independent cause of liver cancer and in evaluating the likely
interactions with the hepatitis viruses in humans. A word of caution
should be raised regarding the interpretation of the early studies
because of: 1) the small sample size and limited methodology as to the
criteria of specimen inclusion; 2) inadequate adjustment of the
correlations for exposures to other viral and non-viral risk factors
at the individual level; 3) limited information on the sensitivity and
specificity of the proposed genetic markers; in particular, some
animal data and cell system data are inconsistent in showing a
specific association between p53 codon 249 mutations and previous
exposure to aflatoxin; and 4) insufficient knowledge of the additional
genetic changes in p53 and other genes (i.e., N-ras, C-myc, c-fos,
alpha-TGF) associated with liver cancer development.
2.2.10.3 Epidemiology of primary liver cancer
(a) Descriptive epidemiology.
Liver cancer is a disease prevalent in some of the developing
parts of the world. It is frequent in China, South East Asia and
subsaharan Africa. In some of these regions, like the Qidong area in
Southern China, liver cancer is the major cause of death to cancer
among men. It is relatively common in Japan and in the countries in
the Mediterranean basin and it is rare in the Americas and Northern
Europe. Pockets of high risk populations have been described in the
Amazonian basin, among Eskimos and in special populations like the
renal transplant patients. The incidence of liver cancer is
consistently higher in men than in women with a sex ratio ranging from
2 to 3 in most countries. Within countries, further variation in
incidence rates is observed across cancer registries, men showing
greater variation than women. Worldwide, the incidence of liver cancer
in men and women shows a strong correlation.
Migration from high risk areas to lower risk areas tends to
reduce the risk to the levels of the host country, and this is
observable within first and second generations.
(b) Etiology
The etiology of primary liver cancer is nowadays largely
understood. Table 1 summarizes the range and the point estimates of
the attributable fractions in two different settings, the low-risk
areas in Europe and the USA and the high-risk areas in Africa and
Asia.
In both scenarios, viral infections to hepatitis B or C virus are
associated with liver cancer in a range from 65% to 100% of cases. In
low-risk countries HBV predominates and the other relevant factors are
alcohol, tobacco and oral contraceptives. In high-risk areas HBV
predominates and aflatoxins play a role, although quantification has
been difficult.
The evidence points to a synergistic interaction between HBV and
AF in the etiology of liver cancer and some debate exists as to the
independency of AF as an etiologic agent in humans.
It is noteworthy that the large majority of the available
epidemiological studies including data on aflatoxin exposure are based
on high-risk countries where both HBV and AF are highly prevalent.
Since the nature of the interaction at low levels of exposure is
unknown, extrapolation of results from available studies to other
settings is questionable.
In addition to these established factors, studies have identified
other factors that may modulate the incidence of the disease. Risk
factors identified are the use of contaminated drinking-water, liver
flukes and severe malnourishment. Protection from liver cancer has
Table 1. Causal factors of liver cancer and estimates of the attributable fractions
Factor Low-risk countries High-risk countries
Japan Europe and the USA Africa and Asia
Estimate Range Estimate Range Estimate Range
Hepatitis B <15% 4-50% 20% 18-44% 60% 40-90%
Hepatitis C3 60% 12-64% 50% 40-80% <10% NE
Aflatoxin limited exposure limited exposure important exposure1
Alcohol <15%4 <20% 11-30%5 NE
Tobacco <12%4 40% 38-51%5 NE
Oral contraceptive 10-50%2 NE NE
Other <5% <5%
1 Attributable risk not quantified. One study suggested attributable fraction close
to 50%.
2 Restricted to liver cancer in women. Likely to increase in future generations.
Uncertain if hepatitis infections (notably HCV) are necessary co-factors.
3 Not including double infections with HBV and HCV. Very few studies available using
second-generation assays.
4 Estimates for the USA
5 Estimates from three studies of LC in men
NE non evaluated.
Note: attributable fractions do not necessarily add to 100% due to multiple exposures and
possible interactions between risk factors.
Adapted from CDC, 1989; Bosch & Muñoz, 1991; Thomas, 1991; Tanaka et al., 1993; IARC,
1994; Bosch, 1995
been reported in the case of diets rich in retinol and protein.
Associations have been reported between liver cancer and blood
testosterone levels, HLA types, and predisposition due to
polimorphisms in some of the SGT and CYT metabolic regulatory genes.
(c) Vaccination against HBV as a preventive measure against liver
cancer
In 1983, the World Health Organization proposed as a medium-term
objective trials of immunization against hepatitis B to prevent liver
cancer. Since then more than 70 countries have introduced HBV
vaccination into their routine vaccination schemes. A recently
published study in Taiwan (Chang et al., 1997) has described the
rigorous application of universal immunization against hepatitis B and
the prevention of the carrier state in children; these data provide
further evidence of a direct causal relationship between HBV and liver
cancer.
The immunization programme against hepatitis B in Taiwan, an area
of hyperendemic infection and moderate to high aflatoxin exposure,
reduced the rate of HBV carriage in six-year-old children from about
10% in the period from 1981 to 1986 to between 0.9 and 0.8% in the
period from 1990 to 1994. The drop in the rate of carriage occurred as
the proportion of infants immunized against hepatitis B increased from
15% of children born to mothers at high risk during the earlier period
to 84-94% of all newborn infants during the later period. This
significant reduction in the prevalence of hepatitis B surface antigen
was accompanied by a decline in the average annual incidence of
hepatocellular carcinoma in children 6 to 14 years of age, from 0.7
per 100 000 between 1981 and 1986 to 0.57 between 1986 and 1989 and
0.36 between 1990 and 1994. The incidence of hepatocellular carcinoma
in children 6 to 19 years old fell even more dramatically, from 0.52
among those born between 1974 and 1984 to 0.13 among those born
between 1984 and 1986. As the investigators pointed out, since the
incidence of hepatocellular carcinoma in Taiwan peaks in the sixth
decade of life, it may take 40 years or longer to see an overall
decrease in the rate of hepatocellular carcinoma as a result of the
vaccination programme.
The Committee noted that studies like this one need to be observed
carefully in coming years for the light they may shed on the
relationship between aflatoxin, HBV and liver cancer.
(d) Effects of exposure to aflatoxins
Ahmed et al.(1995) undertook two prospective studies to
determine a possible relationship between perinatal aflatoxin exposure
and neonatal jaundice. First, cord blood samples from 37 neonates who
subsequently developed jaundice and from 40 non-jaundiced (control)
babies were analysed for six major aflatoxins and aflatoxicol.
Peripheral blood samples of both groups were also analysed postnatally
for aflatoxins. In a second study, serum aflatoxin levels of 64
jaundiced neonates admitted from outside the hospital were compared
with levels in 60 non-jaundiced control babies. Aflatoxins were
detected in 14 (38%) cord blood samples of jaundiced neonates and in
nine (23%) of the controls. The mean cord aflatoxin concentration was
highest in jaundiced neonates with septicaemia, but the difference was
not statistically significant. The frequency of detection of
aflatoxins in peripheral blood was not significantly different in
jaundiced and non-jaundiced babies. Aflatoxins were detected in the
blood of over 50% of neonates with jaundice of unknown etiology. There
was no correlation between severity of hyperbilirubinaemia and serum
aflatoxin levels. Further studies are needed to determine the extent
of pre-and postnatal exposure to aflatoxin in Nigerian infants and the
effects of such exposure on fetal and neonatal health, the authors
concluded.
In October 1988, 13 Chinese children died of acute hepatic
encephalopathy in the northwestern state of Perak in peninsular
Malaysia (Lye et al., 1995). Symptoms included vomiting,
haematemesis, seizures, diarrhoea, fever and abdominal pain. All had
liver dysfunction with increased aspartate aminotransferase and
alanine aminotransferase levels greater than 100 IU/litre. The
acuteness of the illness differed from previously reported outbreaks
described in Kenya, India and Thailand; median incubation period for
this outbreak was 8 hours, whereas the exposure was over a period of
days to weeks of consumption of highly contaminated food such as maize
in outbreaks in Kenya and India. Epidemiological investigations
determined that the children had eaten a Chinese noodle, loh see
fun, hours before they died. The attack rates among those who had
eaten the noodles were significantly higher than those who had not
(P < 0.0001). The cases were geographically scattered in six towns in
two districts along the route of distribution of the noodle supplied
by one factory in Kampar town. Aflatoxins were confirmed in the
postmortem samples from patients, but the noodles or their ingredients
were not analysed for aflatoxins. The authors questioned the etiology
of the outbreak.
Ibeh et al. (1994) examined the relationship between aflatoxin
levels in serum of infertile men in comparison with random controls
from the community. The subjects were 100 adult males, yielding 50
semen samples, from men attending infertility clinics at a university
teaching hospital and 50 normal men in the same community. The staple
foods of the men were assayed for aflatoxin content. Aflatoxin was
found in 20 semen samples from the infertile group (40 %) with a mean
concentration of 1.7 µg/ml and four samples from the fertile group
(8%) with a mean concentration of 1.0 µg/ml. Infertile men showed a
higher percentage of spermatozoa abnormality (50%) than the fertile
men (10-15 %).
In a parallel experiment, adult male rats were given an aflatoxin-
contaminated diet (8.5 µg purified AFB1/g of feed) for 14 days while
10 control age-matched rats were fed a normal aflatoxin-free diet
during the same period. Seven days after the withdrawal of aflatoxin
from the diet of test rats, two rats were randomly selected from the
test and control groups, killed and their semen harvested from the
epididymis and vasa deferentia and analysed. The process was repeated
at weekly intervals until four rats were left in the test and control
groups. Thereafter, four fertile adult female rats were introduced to
mate with test and control rats, and rats were observed for 90 days
with an adequate, non-aflatoxin-contaminated diet. Results
showed that rats exposed to dietary aflatoxin experienced changes in
spermatozoal profile which differed in a statistically significant
manner from the control rats; test rats showed depression in the
motility, viability and number of sperm cells which resembled features
seen in semen of infertile men exposed to aflatoxin. The four test
rats who were mated in the conclusion of the study were unable to
effect conception of fertile female rats, while the four control rats
were able to do so.
The authors hypothesized that aflatoxin may affect the
reproductive system by its toxic effect on the liver, leading to the
desquamation of the membranes of hepatocytes, the mitochondria, the
cytosol and the endoplasmic reticulum. This cellular damage could
include inhibition of enzyme synthesis and/or enzyme activities or
inhibition of lipid metabolism or fatty acid synthesis, which may
derail the capacity of the hepatocytes to handle the conversion of
intermediate biomolecules, such as precursor molecules for hormones,
e.g., testosterone and progesterone. Depression or absence of normal
hormone levels could cause a wide range of degenerative changes in
sexual organs. Aflatoxin may also affect the male reproductive system
by causing lysis of sperm cells as a result of constant reversible
reaction with the mycotoxin, binding of the toxin to free and/or bound
amino acids in the seminal fluid, depressing the motility of
spermatozoa and the formation of aflatoxin adducts with nucleic acids,
giving a risk of mutations of the spermatogonia.
El-Nazami et al. (1995) examined the exposure of infants to
aflatoxin M1 (AFM1) and of lactating mothers to AFB1, using AFM1 in
breast milk as a biomarker for exposure to AFB1. Prevalence of AFM1 in
breast milk samples from 73 women from Victoria, Australia
(low-exposure area) and 11 women from Thailand (high-exposure area)
was also compared. Assays were done by both HPLC and by ELISA. AFM1
was detected in 11 samples from Victoria and five samples from
Thailand at median concentrations of 0.071 mg/ml (range 0.028 - 1.031)
and 0.664 ng/ml (range 0.039 - 1.736). Levels of AFM1 were
significantly higher in milk samples from Thailand than in milk
samples from Victoria.
Ankrah et al. (1994) attempted to ascertain if the presumed
intake of dietary aflatoxins (AFB1 and AFG1) has adverse effect on the
liver; aflatoxins were measured in serum, urine and faecal specimens
obtained from a group of 40 apparently healthy adults (11 females and
29 males) from the Greater Accra region of Ghana. Liver status of the
subjects was monitored with serum alpha-fetoprotein (AFP),
alpha-1-antitrypsin (AAT) and direct: total bilirubin ratio. Aliquots
of serum were tested for HBsAg. AFG1, AFB1, AFQ1, and AFM1 were
detected in one or more of the body specimens in 35% of the subjects
(AFB1+ group). Sixty-five per cent of the subjects had only AFG1 in
their body specimens (AFB-group). Serum levels of AFP (greater than 20
ng/ml), AAT (greater than 170 ng/dl) and direct: total bilirubin ratio
(greater than 0.5), which indicated absence of predisposition to liver
cancer in all the subjects but were suggestive of liver inflammation,
were noted in both the AFB+ and AFB1-subjects. None of the subjects
had malaria or hepatitis B virus infection. The authors suggested that
the pattern of distribution of the aflatoxins in the subjects
indicates that the suspected liver inflammation may involve other
factors and may not be only due to present intake levels of
aflatoxins.
(e) Epidemiological studies on dietary aflatoxins and liver cancer
A number of important epidemiological studies have been published
since the Committee's last review of aflatoxins at its thirty-first
meeting (Annex 1, reference 77).
Yeh et al. (1989) examined the roles of the hepatitis B virus
and AFB1 in the development of primary hepatocellular carcinoma (PHC)
in a cohort of 7917 men aged 25 to 64 years old in southern Guangxi,
China, where the incidence of PHC is among the highest in the world.
After accumulating 30 188 person-years of observation, 149 deaths were
observed, 76 (51%) of which were due to PHC. Ninety-one per cent (69
of 76) were HBsAg+ at enrollment into the study in contrast to 23% of
all members of the cohort. Three of the four patients who died of
liver cirrhosis were also HBsAg+ at enrollment. There was no
association between HBsAg positivity and other causes of death. Within
the cohort, there was a 3.5-fold difference in PHC mortality by place
of residence.
To estimate AFB1 exposure, between 1978 and 1984, the Fusui Liver
Cancer Institute regularly sampled and tested staple foods consumed in
the counties of southern Guangxi for contamination by AFB1. Twice a
year, samples of raw foods were collected from all over the region and
analysed for AFB1 content by TLC. An estimated mean level was computed
for each commune as follows. The yearly amount consumed of a given raw
foodstuff was multiplied by the average AFB1 content as determined
from tested samples of raw foodstuffs. These cross-product terms were
then summed over all staple foods, and the resultant figure was
divided by the total population to obtain an estimated intake per
person per year. These population-based levels of AFB1 were correlated
with mortality rates of PHC among members of the cohort by the
communes from which the subjects were derived.
When estimated AFB1 levels in the subpopulations were plotted
against the corresponding mortality rates of PHC, a positive and
almost perfectly linear relationship was observed. On the other hand
the prevalence of HBsAg was very high and homogeneous across the study
areas (range 21.6%-24.7%) and therefore, no significant association
was observed when the prevalence of HBsAg positivity in the
subpopulations was compared with their corresponding rates of PHC
mortality. The authors conclude that despite the "crudeness" of their
exposure estimate, (i.e., population-based instead of personal
exposure assessments), it is reasonable to conclude that AFB1 seems to
play a role in the unusually high rates of PHC in southern Guangxi.
The population prevalence of HBsAg is extraordinarily high in this
study population, almost one in every four adult men being a
positive carrier of HBV. Primary infection occurs very early in this
high-risk population, possibly through vertical transmission from
carrier mothers to infants during the perinatal period, based on a
survey of serum HBsAg in children ages 1 to 9 years in a county
adjacent to Fusui. Even though most cases of liver cancer in this
study did not have histopathological confirmation, the authors
indicate that probably all were PHCs.
The Yeh et al. (1989) report is an early important study showing
that, in a region where HBV is highly prevalent and PLC is common, the
HBV carriers are at very high risk. It further indicates that in an
area of high AFB1 exposure, the PLC mortality rates are higher than in
areas of lower AFB1 exposure. This study provides the basic
information for most potency estimates. Most of the early correlation
studies (with or without HBV consideration) are consistent with the
basic conclusion of the study of Yeh et al. (1989), but other
studies are not (Campbell et al., 1990; Hsing et al., 1991).
However, the study has the general limitations of correlation studies
in which: i) exposure to AFB1 is estimated from raw foodstuffs
available to populations and attributed to individuals; ii) the
correlation between PLC and AFB1 was not adjusted for any of the
possible confounders such as HCV, alcohol, tobacco or nutritional
status as shown in Taiwan by Yu et al. (1995); iii) HBV exposure may
have been underestimated due to lack of use of PCR methodology; iv)
HBsAg prevalence was measured in a 25% sample of the cohort and
attributed to the region.
Campbell et al. (1990) conducted a comprehensive cross-sectional
survey in the People's Republic of China of possible risk factors for
primary liver cancer (PLC) to include 48 survey sites, an
approximately 600-fold aflatoxin exposure range, a 39-fold range of
HCC mortality rates, a 28-fold range of hepatitis B virus surface
antigen (HBsAg+) carrier prevalence, and estimation of exposures for a
large number of other nutritional, dietary and life-style features
(Campbell et al., 1990). PLC mortality was unrelated to aflatoxin
intake, but was positively correlated with HBsAg+ prevalence, plasma
cholesterol, frequency of liquor consumption, and mean daily intake of
cadmium from foods of plant origin. Multiple regression analysis for
various combinations of risk factors showed that aflatoxin exposure
consistently remained unassociated with PLC mortality regardless of
variable adjustment. In contrast, associations of PLC mortality with
HBsAg+, plasma cholesterol, and cadmium intake remained, regardless of
model specifications, while the association with liquor consumption
was markedly attenuated (nonsignificant) with adjustment for plasma
cholesterol.
The authors commented on the lack of an association between
aflatoxin exposure and PLC mortality in this study, in view of the
findings of most previous investigations. The absence of an
aflatoxin-PLC association was consistent with a similar lack of
association of PLC mortality with the consumption of the two foods
most commonly contaminated with aflatoxin i.e. maize and mouldy
groundnuts. In contrast to the lack of an association with aflatoxin,
PLC mortality was highly correlated with HBsAg+ prevalence and not
with past HBV infection, as assessed by the prevalence of antibody to
the HBV core protein. In this study, the association of plasma
cholesterol with PLC mortality was even more consistent than the
association of PLC mortality with HBsAg+ prevalence. Mortalities from
colon cancer, rectal cancer, lung cancer, leukemia, brain cancer and
total aggregate cancer are also known to be associated with plasma
cholesterol. This association was even more surprising in China where
plasma cholesterol in this cohort ranged up to about 190 mg/dl, which
is near the low end of the range for comparable Western subjects (Chen
et al., 1990).
The authors offered several explanations for the lack of an
association between aflatoxin intake and PLC mortality, which
contrasts with the finding of other previous studies. First, Chinese
people might respond differently to aflatoxin, perhaps because of
unique genetic or environmental characteristics. This is unlikely
given the previously shown positive association between aflatoxin
intake and PLC mortality in Chinese subjects (Yeh et al., 1985; Yeh
et al., 1989) and because major ethnic differences in risk for other
cancers are greatly reduced or eliminated after migration to new
environments.
A second argument could be that the lack of an effect in this
study may have been because measurement of aflatoxin exposure during
the survey period was not representative of past intakes when the
cancers were forming. However, a similar limitation existed for all
other Chinese studies; this study is more reliable, in the opinion of
the authors, because it is based on urinary aflatoxin metabolite
excretion which directly represents and integrates over a day or so
actual consumption. In addition, aflatoxin contamination rates in a
county in the Guangxi Autonomous Region were relatively stable during
the years 1972-1983.
A third line of reasoning suggests that aflatoxin may not be a
significant human carcinogen, in the opinion of the authors. The
present study has greater statistical power and more comprehensive
range, diversity and inclusiveness of risk factors than other previous
studies. Humans may also be resistant to aflatoxin carcinogenesis, a
finding which is supported by in vitro aflatoxin studies on species
of varying resistance (Booth et al., 1981). Humans may also be more
refractory when consuming lower protein diets; whereas acute toxicity
of aflatoxin is increased in protein-malnourished children (Hendrickse
et al., 1982).
The authors pointed out that data from animal studies have shown
that when animals were fed either lower levels of animal protein (5-
or the same level (20%) of plant protein after completion of aflatoxin
dosing, development or preneoplastic lesions and tumours was markedly
inhibited (Appleton & Campbell, 1983; Schulsinger et al., 1989).
Protein in the Chinese diet is primarily of plant or fish origin, as
compared to protein in the USA diet which is primarily of animal
origin (Food and Nutrition Board, 1989; Chen et al., 1990).
The authors continued with a critique of previous aflatoxin
epidemiology studies and offered the following model to explain the
etiology of PLC. The vast majority of individuals who are susceptible
to PLC are those who are persistently infected with HBV. Within this
HBsAg+ population, additional risk is contributed chiefly by
nutritional and dietary practices that enhance liver cell
proliferation, such as diets containing significant amounts of animal
protein. Aflatoxin may act as a carcinogenic initiator, but
contributes only a very small proportion of the initiating activity
routinely exposing the liver. Therefore, HBsAg+ is a necessary but
insufficient cause of PLC, aflatoxin is an unnecessary and
insufficient cause, and sustained nourishment causing liver cell
proliferation (and elevated plasma cholesterol) is a necessary and
insufficient cause for HBsAg negative carriers, but a necessary and
sufficient cause for HBsAg positive carriers. Why is PLC so much more
common in undernourished and impoverished societies? The authors
concluded that PLC is more common because HBsAg+ carriers are more
common.
In evaluating the significance of this study by Campbell et
al. (1990), a number of issues, both statistical and
non-statistical, should be considered. For example, PLC rates were
determined for the years 1973-1975 and the biochemical analyses
(covariate ascertainment) was conducted in 1983. With regard to the
statistical analysis presented in the paper, there is some indication
that the sample data do not adequately satisfy the normality
assumptions upon which the univariate correlation and multiple
regression analyses are based. Finally, the urinary aflatoxin
measurements were of total aflatoxin metabolites, which have been
shown not to correlate well with levels of AFB1 consumed (Wild
et al., 1992; Groopman et al., 1993).
(f) What can we learn from epidemiological studies that considered
HBV, HCV and AFB in relation to liver cancer?
Viral hepatitis is a major worldwide public health problem. It is
estimated that over 300 million individuals are chronically infected
with HBV and perhaps 100 million with HCV. Chronic infection with
either virus has been linked to cirrhosis and liver cancer. HBV is
prevalent in the developing parts of the world, and HCV is emerging as
a major cause of hepatocellular cancer in Japan and western societies
(Table 1).
Tests to detect HBV markers have increased in sensitivity, largely
due to the use of the polymerase chain reaction (PCR) to amplify HBV
DNA in serum and liver tissues. HBV infection has been shown to
persist in the serum (49.7%) or in the liver cancer tissue (24.9%) in
a number of patients with liver cancer that are at the same time HBSAg
negative (Bosch & Muñoz, 1991). This pattern has been documented in
cases from areas at low and high risk for HBV infection.
Although the significance of detecting low levels of HBV DNA in a
patient with liver cancer is not fully understood, from an
epidemiological viewpoint, these subjects could easily be classified
as persistently exposed to HBV and grouped with the HBsAg carriers in
computing risk estimates. Although data are sparse on the prevalence
of equivalent markers in the general population, it is likely that
among controls the prevalence of PCR-detected HBV DNA in the absence
of any other HBV marker is extremely low. If this is the case, the
case control studies that use PCR would increase the Risk Ratio
estimates for HBV as well as the estimates of the Attributable
Fraction. There are no case control studies that have used PCR methods
(in serum or liver tissue) to detect HBV exposure.
Ramesh & Panda (1993) have questioned the hypothesis that HBV
causes chronic liver disease and liver cell carcinoma in
HBsAg-positive individuals only. The presence of HBV in patients with
HCC who are seropositive for the envelope antigen (HBsAg) is well
established. Epidemiological studies have shown a small percentage of
patients with HCC with past HBV infection, positive for anti-HBsAb or
HBcAb. However, the role of HBV in HCC cases who seroconverted from
HBsAg to HBsAb is unclear. The authors described a study of 36 HCC
cases where four cases negative for HBsAg and with underlying
cirrhosis were found. Biopsy tissue was investigated by polymerase
chain reaction; all four samples tested were positive for a portion of
the surface region (nucleotide position: 636-735), but were negative
for the "X" and the "C" regions of HBV genome. Since hepatitis C virus
(HCV) has been associated with HCC, the authors tested serum samples
of the four cases for anti-HCV; one out of four was positive for
anti-HCV. The authors concluded that these observations indicate that
parts of the HBV genome can persist in liver cells of individuals who
have recovered from clinical illness and seroconverted to HBsAg
positive. However, the significance of these sub-genomic fragments in
the development of HCC is not clear.
The identification of HCV in the last decade has been a major step
forward in the understanding of the origins of liver cancer and in the
quantification of the proportion of cases related directly to viral
infections (IARC, 1994). Epidemiological studies are largely
consistent in showing a strong association between carriers of
anti-HCV and liver cancer. The specific potential to induce PLC by
each of the HVC types and variants of types as well as the impact of
other factors from the host and the environment still requires further
research. Likewise, few studies are available exploring the role of
aflatoxin in the presence of HBV and HCV. High estimates of the
Relative Risk for carriers of anti-HCV have also been reported in
areas of HBV endemicity. The risk linked to HCV is independent of HBV
and persons who are carriers of both HBsAg and anti-HCV are at a very
high risk of developing liver cancer. HCV is likely to be the major
cause of liver cancer in countries at low/intermediate risk like the
USA and Europe.
(g) Epidemiological studies including aflatoxins in countries where
the risk of liver cancer is low
In countries where liver cancer is rare and aflatoxin exposure is
low, most etiological studies on liver cancer have not considered
aflatoxins as a risk factor. The populations with higher exposures are
the workers occupationally exposed to grain dust in the animal feed
processing plants. In studies conducted in the Nordic countries in
Europe, Sweden, Denmark, the Netherlands and in the USA, aflatoxins
have been isolated from dust samples and an excess of mortality of
several such cohorts has been documented for liver cancer (risk, 2.4
times the expected rates) liver and biliary tract cancer (risk, 2.5
times the expected rates), lung cancer and lymphomas (risk, 1.5-3
times the expected rates (Hayes et al., 1984; Alavanja et al.,
1987; Olsen et al., 1988). It should be noted that some of these
studies did not evaluate other relevant exposures such as hepatitis
infections and alcohol.
It is of interest that few studies are available on liver cancer
in Latin America. In this extensive region of the world, agricultural
products are prone to mould growth, and consumption of maize is part
of the staple food in many countries. Yet liver cancer is rare in
these populations as is HBV infection. If that is the case, Latin
America would be potentially a very informative field to investigate
the occurrence of liver cancer in populations exposed to AF as the
central risk factor.
(h) Epidemiological studies that used biomarkers of exposure to
aflatoxins including studies on genetic susceptibility to aflatoxins
Biomarkers have been developed and are being introduced in
epidemiological studies with the purpose of increasing the accuracy of
the assessment of exposure to aflatoxins. Various biomarkers have been
developed, including urinary total aflatoxins, aflatoxin adducts in
urine, aflatoxin albumin adduct in serum, aflatoxin adducts in liver
cancer tissue and more recently p53 specific mutations in liver cancer
specimens. Other studies are investigating genetic polymorphisms in
some key genes involved in the metabolism of aflatoxin that may
introduce some variability in the response to aflatoxin. (Groopman
et al., 1994; Wild et al., 1996; IARC, 1997).
The importance of the major aflatoxin-nucleic acid adduct,
AFB-N7-guanine, in urine as a biomarker was enhanced by the finding
that this metabolite is excreted exclusively in urine of exposed rats,
thus simplifying pharmacokinetic considerations. The aflatoxin-albumin
adduct in serum has also been examined as a biomarker of exposure;
because of the longer half-life in vivo of albumin compared to the
urinary AFB-N7-guanine, the serum albumin adduct can integrate
exposures over longer time periods. Data from human exposure studies
have shown that the excretion of the urinary aflatoxin nucleic acid
adduct and formation of the serum albumin adduct are highly
correlated. In the rat, validation studies for the dose-dependent
excretion of urinary aflatoxin biomarkers were conducted in rats
following a single exposure to AFB1; excellent linear correspondence
between oral AFB1 dose and excretion of AFB-N7-guanine in urine was
shown (Scholl et al., 1995).
Aflatoxin metabolites in urine or adducts in serum can be a useful
tool to evaluate exposure but with the currently available methods
remain relatively short-term exposure markers; biomarkers are of much
less use in predicting long-term or lifetime human exposure. As such,
they reflect poorly the natural pattern of exposure to aflatoxin
(i.e., seasonality, manual sorting of foodstuffs, age at exposure,
etc.); therefore, it is not surprising that studies conducted using
aflatoxin biomarkers as markers of exposure show conflicting results.
At present, it is not fully understood how the functional status
of the liver or the coexistence of other risk factors for liver cancer
may affect the different biomarkers that are being proposed for
epidemiological studies. Few studies have described the natural
history of these markers in patients with chronic liver disease
including chronic hepatitis and liver cirrhosis, conditions that
usually precede liver cancer by months or years (Wild et al., 1993;
Wang et al., 1996a). In this circumstance, the interpretation of the
findings is complicated since the aflatoxin biomarker may be
confounded by the presence of some risk factors, (e.g., HBV, HCV,
alcohol), the presence of some protective factors (e.g., retinol in
the diet) or by the presence of liver disease (i.e. chronic active
hepatitis B infection).
The mutations in the p53 gene claimed to be specific markers of
exposure to aflatoxin are being actively investigated to confirm the
strength and the specificity of the association in human populations
(Harris, 1995). Recent data have been summarized earlier in this
paper.
The best evidence of an interaction between HBV and aflatoxin in
the causation of human liver cancer is the cohort study in Shanghai
(Ross et al., 1992, Qian et al., 1994; Yuan et al., 1995). This
is an ongoing prospective study of 18 244 middle-aged men in Shanghai,
China. Assays for urinary AFB1, its metabolites AFP1 and AFM1 and DNA
adducts have been performed to assess the relationship between
aflatoxin exposure and liver cancer. After 35 299 person-years of
follow-up, 22 cases of liver cancer had been identified. For each
case, 5 or 10 controls were randomly selected from cohort members
without liver cancer on the date the disorder was diagnosed in the
case and matched to within 1 year of age, within 1 month for sample
collection, and for neighbourhood of residence. Each subject provided
a blood sample and a urine sample. A positive result was defined as
the presence of at least 1 ng of an individual aflatoxin compound in
the sample. Hepatitis B surface antigen was measured by a standard
radioimmunoassay method.
Subjects with liver cancer were significantly more likely than
were controls to have detectable concentrations of any of the
aflatoxin compounds; the strongest association was for AFP1.
Positivity for HBsAg was strongly associated with risk of liver
cancer. The authors concluded that their results are based on too few
cases to give a reliable estimate of attributable risk, but they
estimated that up to 50% of cases of liver cancer in Shanghai may be
due to aflatoxin exposure.
In further follow-up of the Shanghai study, Qian et al. (1994)
reported on 70 000 person-years of follow-up and 55 cases of HCC.
Levels of urinary AFB1 and the oxidative metabolites, including the
major aflatoxin nucleic acid adduct, aflatoxin-N7-guanine, were
determined for 50 of the 55 identified cases of HCC; 267 controls were
matched against the 50 cases as above. A nested case-control analysis
showed highly significant association between the